The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.
|
1. A method for the preparation of a long-term storage stable adenovirus liquid formulation, comprising providing adenovirus and combining said adenovirus with a solution comprising a buffer and a polyol, whereby said adenovirus liquid formulation retains high infectivity.
16. A method for the preparation of a long-term storage stable adenovirus liquid formulation, comprising providing adenovirus and combining said adenovirus with a solution comprising a buffer, a polyol, and a non-ionic detergent, whereby said adenovirus liquid formulation retains high infectivity.
22. A method for the preparation of a long-term storage stable adenovirus liquid formulation, comprising providing adenovirus and combining said adenovirus with a solution comprising a buffer, a polyol; and a salt selected from the group consisting of MgCl2, MnCl2, Ca Cl2, ZnCl2, NaCl, and KCl, whereby said adenovirus liquid formulation retains high infectivity.
2. The method of
3. The method of
4. The method of
5. The method of
7. The method of
8. The method of
13. The method of
17. The method of
18. The method of
19. The method of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a divisional of co-pending U.S. patent application Ser. No. 11/768,796, filed Jun. 26, 2007, which is a continuation of U.S. patent application Ser. No. 09/941,296, filed Aug. 28, 2001 (now issued as U.S. Pat. No. 7,235,391), which is a divisional of U.S. patent application Ser. No. 09/441,410, filed Nov. 16, 1999 (now issued as U.S. Pat. No. 6,689,600), which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/133,116, filed May 7, 1999, and U.S. Provisional Patent Application Ser. No. 60/108,606, filed Nov. 16, 1998. The entire contents of these applications are incorporated by reference.
A. Field of the Invention
The present invention relates generally to the fields of molecular biology, virus production and gene therapy. More particularly, it concerns methods for the formulation of highly purified lyophilized and liquid adenovirus particles stable for long-term storage. An important embodiment of the present invention is the use of such long-term storage virus preparations for gene therapy treatments of viral disease, genetic disease and malignancies.
B. Description of Related Art
Viruses are highly efficient at nucleic acid delivery to specific cell types, while often avoiding detection by the infected hosts immune system. These features make certain viruses attractive candidates as gene-delivery vehicles for use in gene therapies (Robbins and Ghivizzani; 1998; Cristiano et al., 1998). Retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus are examples of commonly used viruses in gene therapies. Each of the aforementioned viruses has its advantages and limitations, and must therefore be selected according to suitability of a given gene therapy (Robbins and Ghivizzani; 1998).
A variety of cancer and genetic diseases currently are being addressed by gene therapy. Cardiovascular disease (Morishita et al., 1998), colorectal cancer (Fujiwara and Tanaka, 1998), lung cancer (Roth et al., 1998), brain tumors (Badie et al., 1998), and thyroid carcinoma (Braiden et al., 1998) are examples of gene therapy treatments currently under investigation. Further, the use of viral vectors in combination with other cancer treatments also is an avenue of current research (Jounaidi et al., 1998).
Viral particles must maintain their structural integrity to be infectious and biologically active. The structural integrity of a viral vector often is compromised during the formulation process, thus precluding its use as a gene therapy vector. Adenoviruses for gene therapy traditionally have been formulated in buffers containing 10% glycerol. Formulated adenovirus is stored at <−60° C. to ensure good virus stability during storage. This ultra-low temperature storage not only is very expensive, but creates significant inconvenience for storage, transportation and clinic use. There is an urgent need to develop new formulation for adenovirus that can be stored at refrigerated condition.
Lyophilization has been used widely to improve the stability of various viral vaccine and recombinant protein products. It is expected that the long-term storage stability of adenovirus can be improved by reducing the residual water content (moisture) in the formulated product through lyophilization. However, there have not been reported studies on the lyophilization of live adenovirus for gene therapy.
Generally it is assumed that adenovirus will not maintain its infectivity when stored at refrigerated condition in a liquid form for extended period of time. As a result, there are no reported studies on formulating and storing adenovirus at refrigerated condition in a liquid form. Thus, there remains a need for long-term storage stable formulations of viral preparations.
The present invention addresses the need for improved, storage stable viral formulations, and methods for the production thereof, for use in gene therapy. In particular embodiments, a pharmaceutical adenovirus composition comprising adenovirus particles and pharmaceutical excipients, the excipients including a bulking agent and one or more protectants, wherein the excipients are included in amounts effective to provide an adenovirus composition that is storage stable. In preferred embodiments, the adenovirus composition has an infectivity of between 60 and 100% of the starting infectivity, and a residual moisture of less than about 5%, when stored for six months at 4° centigrade.
In one embodiment, the adenovirus composition is a freeze dried composition. In particular embodiments, the bulking agent in the freeze dried adenovirus composition forms crystals during freezing, wherein the bulking agent is mannitol, inositol, lactitol, xylitol, isomaltol, sorbitol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silcate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose or methylcellulose.
In certain embodiments, the bulking agent in the freeze dried adenovirus composition is mannitol. In other embodiments the composition is further defined as an aqueous composition comprising mannitol in a concentration of from about 1% to about 10% (w/v). In another embodiment, the aqueous composition comprises the mannitol in a concentration of from about 3% to 8%. In a preferred embodiment, the aqueous composition comprises mannitol in a concentration of from about 5% to 7%.
In certain embodiments, the freeze dried composition is prepared from an aqueous composition comprising a bulking agent in a concentration of from about 1% to 10% (w/v). In other embodiments the freeze dried composition is prepared from an aqueous composition comprising a bulking agent in a concentration of from about 3% to 8%. In yet other embodiments, the freeze dried composition is prepared from an aqueous composition comprising a bulking agent in a concentration of from about 5% to 7%.
In particular embodiments, pharmaceutical excipients serve as a protectants. In one embodiment, the protectant is further defined as a cryoprotectant. In certain embodiments, the cryoprotectant is a non-reducing sugar. In particularly defined embodiments the non-reducing sugar is sucrose or trehalose. In preferred embodiments the non-reducing sugar is sucrose.
In certain embodiments, the composition is further defined as an aqueous composition comprising a non-reducing sugar in a concentration of from about 2% to about 10% (w/v). In other embodiments, the aqueous composition comprises the sugar in a concentration of from about 4% to 8%. In still other embodiments, the aqueous composition comprises the sugar in a concentration of from about 5% to 6%.
In one embodiment, the freeze dried composition is prepared from an aqueous composition comprising a non-reducing sugar in a concentration of from about 2% to 10% (w/v). In other embodiments, the freeze dried composition is prepared from an aqueous composition comprising a non-reducing sugar in a concentration of from about 4% to 8%. In yet other embodiments, the freeze dried composition is prepared from an aqueous composition comprising a non-reducing sugar in a concentration of from about 5% to 6%.
In another embodiment, the cryoprotectant is niacinamide, creatinine, monosodium glutamate, dimethyl sulfoxide or sweet whey solids.
In certain embodiments, the protectant includes a lyoprotectant, wherein the lyoprotectant is human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 or Tween-80. In a preferred embodiment, the lyoprotectant is human serum albumin.
In certain embodiments, the composition is further defined as an aqueous composition comprising the lyoprotectant in a concentration of from about 0.5% to about 5% (w/v). In another embodiment, the aqueous composition comprises the lyoprotectant in a concentration of from about 1% to about 4%. In still another embodiment, the aqueous composition comprises the lyoprotectant in a concentration of from about 1% to about 3%.
In particular embodiments, the freeze dried composition is prepared from an aqueous composition comprising a lyoprotectant in a concentration of from about 0.5% to 5% (w/v). In other embodiments, the freeze dried composition is prepared from an aqueous composition comprising a lyoprotectant in a concentration of from about 1% to 4%. In another embodiment, the freeze dried composition is prepared from an aqueous composition comprising a lyoprotectant in a concentration of from about 1% to 3%.
In one embodiment, pharmaceutical excipients defined as protectants, comprise both a lyoprotectant and a cryoprotectant.
Also contemplated in the present invention is an aqueous pharmaceutical adenovirus composition comprising a polyol in an amount effective to promote the maintenance of adenoviral infectivity. In one embodiment, adenoviral infectivity of the adenovirus polyol composition is further defined as maintaining an infectivity of about 70% PFU/mL to about 99.9% PFU/mL of the starting infectivity when stored for six months at 40 centigrade. In preferred embodiments, adenoviral infectivity is about 80% to 95% PFU/mL of the starting infectivity when stored for six months at 40 centigrade.
In the context of the present invention, a polyol is defined as a polyhydric alcohol containing two or more hydroxyl groups. In certain embodiments, the polyol is glycerol, propylene glycol, polyethylene glycol, sorbitol or mannitol, wherein the polyol concentration is from about 5% to about 30% (w/v). In other embodiments, the polyol concentration is from about 10% to about 30%. In yet other embodiments, the polyol concentration is about 25%.
In a preferred embodiment, the aqueous pharmaceutical adenovirus composition comprises a polyol in an amount effective to promote the maintenance of adenoviral infectivity, wherein the polyol is glycerol, included in a concentration of from about 5% to about 30% (w/v).
In other embodiments, the aqueous pharmaceutical adenovirus composition comprising a polyol in an amount effective to promote the maintenance of adenoviral infectivity further comprises an excipient in addition to the polyol, wherein the excipient is inositol, lactitol, xylitol, isomaltol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silicate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose, methylcellulose, sucrose, dextrose, lactose, trehalose, glucose, maltose, niacinamide, creatinine, monosodium glutamate dimethyl sulfoxide, sweet whey solids, human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 or Tween-80.
In further defined embodiments, the aqueous pharmaceutical adenovirus composition comprising a polyol further comprises in addition to the polyol at least a first and a second excipient, wherein the second excipient is different the first excipient, and the excipient is inositol, lactitol, xylitol, isomaltol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silicate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose, methylcellulose, sucrose, dextrose, lactose, trehalose, glucose, maltose, niacinamide, creatinine, monosodium glutamate dimethyl sulfoxide, sweet whey solids, human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 or Tween-80.
In another embodiment of the present invention, a method for the preparation of a long-term, storage stable adenovirus formulation, comprising the steps of providing adenovirus and combining the adenovirus with a solution comprising a buffer, a bulking agent, a cryoprotectant and a lyoprotectant; and lyophilizing the solution, whereby lyophilization of the solution produces a freeze-dried cake of the adenovirus formulation that retains high infectivity and low residual moisture.
In particular embodiments, the bulking agent used for preparing the freeze dried adenovirus formulation is mannitol, inositol, lactitol, xylitol, isomaltol, sorbitol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silcate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose or methylcellulose. In preferred embodiments, the bulking agent is mannitol, wherein mannitol comprises about 0.5% to about 8% (w/v) of the formulation.
In other embodiments, the cryoprotectant used for preparing the freeze dried adenovirus formulation is sucrose, dextrose, lactose, trehalose, glucose, maltose, niacinamide, creatinine, monosodium glutamate dimethyl sulfoxide or sweet whey solids. In preferred embodiments, the cryoprotectant is sucrose, wherein sucrose comprises about 2.5% to about 10% (w/v) of said formulation.
In further embodiments, the lyoprotectant used for preparing the freeze dried adenovirus formulation is human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 or Tween-80. In preferred embodiments, the lyoprotectant is human serum albumin.
In other embodiments, the buffer used for preparing the freeze dried adenovirus formulation is Tris-HCl, TES, HEPES, mono-Tris, brucine tetrahydrate, EPPS, tricine, or histidine, wherein the buffer is present in the formulation at a concentration at about 1 mM to 50 mM. In one preferred embodiment, the buffer used for preparing the freeze dried adenovirus formulation is Tris-HCl, wherein the Tris-HCl is included in a concentration of from about 1 mM to about 50 mM. In another embodiment, the Tris-HCl is included in a concentration of from about 5 mM to about 20 mM. In still other embodiments, the freeze dried adenovirus formulation further comprises a salt selected from the group consisting of MgCl2, MnCl2, Ca Cl2, ZnCl2, NaCl and KCl.
In one embodiment, lyophilizing the adenovirus formulation is carried out in the presence of an inert gas.
In certain embodiments, the method for preparing the freeze dried adenovirus formulation, wherein lyophilizing the solution comprises the steps of, freezing the solution, subjecting the solution to a vacuum and subjecting the solution to at least a first and a second drying cycle, whereby the second drying cycle reduces the residual moisture content of the freeze-dried cake to less than about 2%.
In another embodiment, a method for the preparation of a long-term storage, stable adenovirus liquid formulation, comprising the steps of providing adenovirus and combining the adenovirus with a solution comprising a buffer and a polyol, whereby the adenovirus liquid formulation retains high infectivity.
Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
The need for long-term stable virus formulations that can be stored at or above refrigerated temperatures without losing infectivity is highly desirable. Traditional methods of ultra-low temperature storage (≦60° C.) of virus preparations often limit the storage, transportation and clinical applications of viruses. The inventors have developed optimal lyophilization formulations for freeze-drying adenovirus in which the freeze-dried products maintain their stability (i.e., infectivity of 60-100% of the starting infectivity) and have a residual moisture of less than about 5% when stored for 6 months at 4° C.
In another embodiment, the inventors have developed long-term stable adenovirus formulations for storing adenovirus at 4° C. in a liquid form that maintains stability (i.e., infectivity of 60-100% of the starting infectivity) for at least 6 months.
A large scale process for the production and purification of adenovirus is described in U.S. Ser. No. 08/975,519 filed Nov. 20, 1997 (specifically incorporated herein by reference without disclaimer). This production process offers not only scalability and validatability but also virus purity comparable to that achieved using CsCl gradient ultracentrifugation. This process involves the preparation of recombinant adenovirus particles, the process comprising preparing a culture of producer cells by seeding producer cells into a culture medium, infecting cells in the culture after mid-log phase growth with a recombinant adenovirus comprising a selected recombinant gene operably linked to a promoter, harvesting recombinant adenovirus particles from the cell culture and removing contaminating nucleic acids. An important aspect of this process is the removal of contaminating nucleic acids using nucleases. Exemplary nucleases include Benzonase®, Pulmozyme®; or any other DNase or RNase commonly used within the art.
Enzymes such as Benzonaze® degrade nucleic acid and have no proteolytic activity. The ability of Benzonase® to rapidly hydrolyze nucleic acids makes the enzyme ideal for reducing cell lysate viscosity. It is well known that nucleic acids may adhere to cell derived particles such as viruses. The adhesion may interfere with separation due to agglomeration, change in size of the particle or change in particle charge, resulting in little if any product being recovered with a given purification scheme. Benzonase® is well suited for reducing the nucleic acid load during purification, thus eliminating the interference and improving yield.
As with all endonuclease, Benzonase® hydrolyzes internal phosphodiester bonds between specific nucleotides. Upon complete digestion, all free nucleic acids present in solution are reduced to oligonucleotides 2 to 4 bases in length.
The present invention further employs a number of different purification techniques to purify viral vectors of the present invention. Such techniques include those based on sedimentation and chromatography and are described in more detail herein below.
1. Density Gradient Centrifugation
There are two methods of density gradient centrifugation, the rate zonal technique and the isopycnic (equal density) technique, and both can be used when the quantitative separation of all the components of a mixture of particles is required. They are also used for the determination of buoyant densities and for the estimation of sedimentation coefficients.
Particle separation by the rate zonal technique is based upon differences in size or sedimentation rates. The technique involves carefully layering a sample solution on top of a performed liquid density gradient, the highest density of which exceeds that of the densest particles to be separated. The sample is then centrifuged until the desired degree of separation is effected, i.e., for sufficient time for the particles to travel through the gradient to form discrete zones or bands which are spaced according to the relative velocities of the particles. Since the technique is time dependent, centrifugation must be terminated before any of the separated zones pellet at the bottom of the tube. The method has been used for the separation of enzymes, hormones, RNA-DNA hybrids, ribosomal subunits, subcellular organelles, for the analysis of size distribution of samples of polysomes and for lipoprotein fractionations.
The sample is layered on top of a continuous density gradient which spans the whole range of the particle densities which are to be separated. The maximum density of the gradient, therefore, must always exceed the density of the most dense particle. During centrifugation, sedimentation of the particles occurs until the buoyant density of the particle and the density of the gradient are equal (i.e., where pp=pm in equation 2.12). At this point no further sedimentation occurs, irrespective of how long centrifugation continues, because the particles are floating on a cushion of material that has a density greater than their own.
Isopycnic centrifugation, in contrast to the rate zonal technique, is an equilibrium method, the particles banding to form zones each at their own characteristic buoyant density. In cases where, perhaps, not all the components in a mixture of particles are required, a gradient range can be selected in which unwanted components of the mixture will sediment to the bottom of the centrifuge tube whilst the particles of interest sediment to their respective isopycnic positions. Such a technique involves a combination of both the rate zonal and isopycnic approaches.
Isopycnic centrifugation depends solely upon the buoyant density of the particle and not its shape or size and is independent of time. Hence soluble proteins, which have a very similar density (e.g., p=1.3 g cm−3 in sucrose solution), cannot usually be separated by this method, whereas subcellular organelles (e.g., Golgi apparatus, p=1.11 g cm−3, mitochondria, p=1.19 g cm−3 and peroxisomes, p=1.23 g cm−3 in sucrose solution) can be effectively separated.
As an alternative to layering the particle mixture to be separated onto a preformed gradient, the sample is initially mixed with the gradient medium to give a solution of uniform density, the gradient ‘self-forming’, by sedimentation equilibrium, during centrifugation. In this method (referred to as the equilibrium isodensity method), use is generally made of the salts of heavy metals (e.g., cesium or rubidium), sucrose, colloidal silica or Metrizamide.
The sample (e.g., DNA) is mixed homogeneously with, for example, a concentrated solution of cesium chloride. Centrifugation of the concentrated cesium chloride solution results in the sedimentation of the CsCl molecules to form a concentration gradient and hence a density gradient. The sample molecules (DNA), which were initially uniformly distributed throughout the tube now either rise or sediment until they reach a region where the solution density is equal to their own buoyant density, i.e. their isopycnic position, where they will band to form zones. This technique suffers from the disadvantage that often very long centrifugation times (e.g., 36 to 48 hours) are required to establish equilibrium. However, it is commonly used in analytical centrifugation to determine the buoyant density of a particle, the base composition of double stranded DNA and to separate linear from circular forms of DNA.
Many of the separations can be improved by increasing the density differences between the different forms of DNA by the incorporation of heavy isotopes (e.g., 15N) during biosynthesis, a technique used by Leselson and Stahl to elucidate the mechanism of DNA replication in Esherichia coli, or by the binding of heavy metal ions or dyes such as ethidium bromide. Isopycnic gradients have also been used to separate and purify viruses and analyze human plasma lipoproteins.
2. Chromatography
Purification techniques are well known to those of skill in the art. These techniques tend to involve the fractionation of the cellular milieu (e.g., density gradient centrifugation) to separate the adenovirus particles from other components of the mixture. Having separated adenoviral particles from the other components, the adenovirus may be purified using chromatographic and electrophoretic techniques to achieve complete purification. Analytical methods particularly suited to the preparation of a pure adenoviral particle of the present invention are ion-exchange chromatography, size exclusion chromatography and polyacrylamide gel electrophoresis. A particularly efficient purification method to be employed in conjunction with the present invention is HPLC.
Certain aspects of the present invention concern the purification, and in particular embodiments, the substantial purification, of an adenoviral particle. The term “purified” as used herein, is intended to refer to a composition, isolatable from other components, wherein the adenoviral particle is purified to any degree relative to its naturally-obtainable form. A purified adenoviral particle therefore also refers to an adenoviral component, free from the environment in which it may naturally occur.
Generally, “purified” will refer to an adenoviral particle that has been subjected to fractionation to remove various other components, and which composition substantially retains its expressed biological activity. Where the term “substantially purified” is used, this designation will refer to a composition in which the particle, protein or peptide forms the major component of the composition, such as constituting about 50% or more of the constituents in the composition.
Various methods for quantifying the degree of purification of a protein or peptide will be known to those of skill in the art in light of the present disclosure. These include, for example, determining the specific activity of an active fraction, or assessing the amount of polypeptides within a fraction by SDS/PAGE analysis. A preferred method for assessing the purity of a fraction is to calculate the specific activity of the fraction, to compare it to the specific activity of the initial extract, and to thus calculate the degree of purity, herein assessed by a “-fold purification number”. The actual units used to represent the amount of activity will, of course, be dependent upon the particular assay technique chosen to follow the purification and whether or not the expressed protein or peptide exhibits a detectable activity.
There is no general requirement that the adenovirus, always be provided in their most purified state. Indeed, it is contemplated that less substantially purified products will have utility in certain embodiments. Partial purification may be accomplished by using fewer purification steps in combination, or by utilizing different forms of the same general purification scheme. For example, it is appreciated that a cation-exchange column chromatography performed utilizing an HPLC apparatus will generally result in a greater-fold purification than the same technique utilizing a low pressure chromatography system. Methods exhibiting a lower degree of relative purification may have advantages in total recovery of protein product, or in maintaining the activity of an expressed protein.
Of course, it is understood that the chromatographic techniques and other purification techniques known to those of skill in the art may also be employed to purify proteins expressed by the adenoviral vectors of the present invention. Ion exchange chromatography and high performance liquid chromatography are exemplary purification techniques employed in the purification of adenoviral particles and are described in further detail herein below.
a. Ion-Exchange Chromatography
The basic principle of ion-exchange chromatography is that the affinity of a substance for the exchanger depends on both the electrical properties of the material and the relative affinity of other charged substances in the solvent. Hence, bound material can be eluted by changing the pH, thus altering the charge of the material, or by adding competing materials, of which salts are but one example. Because different substances have different electrical properties, the conditions for release vary with each bound molecular species. In general, to get good separation, the methods of choice are either continuous ionic strength gradient elution or stepwise elution. (A gradient of pH alone is not often used because it is difficult to set up a pH gradient without simultaneously increasing ionic strength.) For an anion exchanger, either pH and ionic strength are gradually increased or ionic strength alone is increased. For a cation exchanger, both pH and ionic strength are increased. The actual choice of the elution procedure is usually a result of trial and error and of considerations of stability. For example, for unstable materials, it is best to maintain fairly constant pH.
An ion exchanger is a solid that has chemically bound charged groups to which ions are electrostatically bound; it can exchange these ions for ions in aqueous solution. Ion exchangers can be used in column chromatography to separate molecules according to charge; actually other features of the molecule are usually important so that the chromatographic behavior is sensitive to the charge density, charge distribution, and the size of the molecule.
The principle of ion-exchange chromatography is that charged molecules adsorb to ion exchangers reversibly so that molecules can be bound or eluted by changing the ionic environment. Separation on ion exchangers is usually accomplished in two stages: first, the substances to be separated are bound to the exchanger, using conditions that give stable and tight binding; then the column is eluted with buffers of different pH, ionic strength, or composition and the components of the buffer compete with the bound material for the binding sites.
An ion exchanger is usually a three-dimensional network or matrix that contains covalently linked charged groups. If a group is negatively charged, it will exchange positive ions and is a cation exchanger. A typical group used in cation exchangers is the sulfonic group, SO3−. If an H+ is bound to the group, the exchanger is said to be in the acid form; it can, for example, exchange on H+ for one Na+ or two H+ for one Ca2+. The sulfonic acid group is called a strongly acidic cation exchanger. Other commonly used groups are phenolic hydroxyl and carboxyl, both weakly acidic cation exchangers. If the charged group is positive—for example, a quaternary amino group—it is a strongly basic anion exchanger. The most common weakly basic anion exchangers are aromatic or aliphatic amino groups.
The matrix can be made of various material. Commonly used materials are dextran, cellulose, agarose and copolymers of styrene and vinylbenzene in which the divinylbenzene both cross-links the polystyrene strands and contains the charged groups. Table 1 gives the composition of many ion exchangers.
The total capacity of an ion exchanger measures its ability to take up exchangeable groups per milligram of dry weight. This number is supplied by the manufacturer and is important because, if the capacity is exceeded, ions will pass through the column without binding.
TABLE 1
Matrix
Exchanger
Functional Group
Tradename
Dextran
Strong Cationic
Sulfopropyl
SP-Sephadex
Weak Cationic
Carboxymethyl
CM-Sephadex
Strong Anionic
Diethyl-(2-
QAE-Sephadex
hydroxypropyl)-
aminoethyl
Weak Anionic
Diethylaminoethyl
DEAE-Sephadex
Cellulose
Cationic
Carboxymethyl
CM-Cellulose
Cationic
Phospho
P-cel
Anionic
Diethylaminoethyl
DEAE-cellulose
Anionic
Polyethylenimine
PEI-Cellulose
Anionic
Benzoylated-
DEAE(BND)-cellulose
naphthoylated,
deiethylaminoethyl
Anionic
p-Aminobenzyl
PAB-cellulose
Styrene-
Strong Cationic
Sulfonic acid
AG 50
divinyl-
Strong Anionic
AG 1
benzene
Strong Cationic +
Sulfonic acid +
AG 501
Strong Anionic
Tetramethylammonium
Acrylic
Weak Cationic
Carboxylic
Bio-Rex 70
Phenolic
Strong Cationic
Sulfonic acid
Bio-Rex 40
Expoxyamine
Weak Anionic
Tertiary amino
AG-3
The available capacity is the capacity under particular experimental conditions (i.e., pH, ionic strength). For example, the extent to which an ion exchanger is charged depends on the pH (the effect of pH is smaller with strong ion exchangers). Another factor is ionic strength because small ions near the charged groups compete with the sample molecule for these groups. This competition is quite effective if the sample is a macromolecule because the higher diffusion coefficient of the small ion means a greater number of encounters. Clearly, as buffer concentration increases, competition becomes keener.
The porosity of the matrix is an important feature because the charged groups are both inside and outside the matrix and because the matrix also acts as a molecular sieve. Large molecules may be unable to penetrate the pores; so the capacity will decease with increasing molecular dimensions. The porosity of the polystyrene-based resins is determined by the amount of cross-linking by the divinylbenzene (porosity decreases with increasing amounts of divinylbenzene). With the Dowex and AG series, the percentage of divinylbenzene is indicated by a number after an X—hence, Dowex 50-X8 is 8% divinylbenzene
Ion exchangers come in a variety of particle sizes, called mesh size. Finer mesh means an increased surface-to-volume ration and therefore increased capacity and decreased time for exchange to occur for a given volume of the exchanger. On the other hand, fine mesh means a slow flow rate, which can increase diffusional spreading. The use of very fine particles, approximately 10 μm in diameter and high pressure to maintain an adequate flow is called high-performance or high-pressure liquid chromatography or simply HPLC.
Such a collection of exchangers having such different properties—charge, capacity, porosity, mesh—makes the selection of the appropriate one for accomplishing a particular separation difficult. How to decide on the type of column material and the conditions for binding and elution is described in the following Examples.
There are a number of choice to be made when employing ion exchange chromatography as a technique. The first choice to be made is whether the exchanger is to be anionic or cationic. If the materials to be bound to the column have a single charge (i.e., either plus or minus), the choice is clear. However, many substances (e.g., proteins, viruses), carry both negative and positive charges and the net charge depends on the pH. In such cases, the primary factor is the stability of the substance at various pH values. Most proteins have a pH range of stability (i.e., in which they do not denature) in which they are either positively or negatively charged. Hence, if a protein is stable at pH values above the isoelectric point, an anion exchanger should be used; if stable at values below the isoelectric point, a cation exchanger is required.
The choice between strong and weak exchangers is also based on the effect of pH on charge and stability. For example, if a weakly ionized substance that requires very low or high pH for ionization is chromatographed, a strong ion exchanger is called for because it functions over the entire pH range. However, if the substance is labile, weak ion exchangers are preferable because strong exchangers are often capable of distorting a molecule so much that the molecule denatures. The pH at which the substance is stable must, of course, be matched to the narrow range of pH in which a particular weak exchanger is charged. Weak ion exchangers are also excellent for the separation of molecules with a high charge from those with a small charge, because the weakly charged ions usually fail to bind. Weak exchangers also show greater resolution of substances if charge differences are very small. If a macromolecule has a very strong charge, it may be impossible to elute from a strong exchanger and a weak exchanger again may be preferable. In general, weak exchangers are more useful than strong exchangers.
The Sephadex and Bio-gel exchangers offer a particular advantage for macromolecules that are unstable in low ionic strength. Because the cross-links in these materials maintain the insolubility of the matrix even if the matrix is highly polar, the density of ionizable groups can be made several times greater than is possible with cellulose ion exchangers. The increased charge density means increased affinity so that adsorption can be carried out at higher ionic strengths. On the other hand, these exchangers retain some of their molecular sieving properties so that sometimes molecular weight differences annul the distribution caused by the charge differences; the molecular sieving effect may also enhance the separation.
Small molecules are best separated on matrices with small pore size (high degree of cross-linking) because the available capacity is large, whereas macromolecules need large pore size. However, except for the Sephadex type, most ion exchangers do not afford the opportunity for matching the porosity with the molecular weight.
The cellulose ion exchangers have proved to be the best for purifying large molecules such as proteins and polynucleotides. This is because the matrix is fibrous, and hence all functional groups are on the surface and available to even the largest molecules. In may cases however, beaded forms such as DEAE-Sephacel and DEAE-Biogel P are more useful because there is a better flow rate and the molecular sieving effect aids in separation.
Selecting a mesh size is always difficult. Small mesh size improves resolution but decreases flow rate, which increases zone spreading and decreases resolution. Hence, the appropriate mesh size is usually determined empirically.
Because buffers themselves consist of ions, they can also exchange, and the pH equilibrium can be affected. To avoid these problems, the rule of buffers is adopted: use cationic buffers with anion exchangers and anionic buffers with cation exchangers. Because ionic strength is a factor in binding, a buffer should be chosen that has a high buffering capacity so that its ionic strength need not be too high. Furthermore, for best resolution, it has been generally found that the ionic conditions used to apply the sample to the column (the so-called starting conditions) should be near those used for eluting the column.
b. High Performance Liquid Chromatography
High performance liquid chromatography (HPLC) is characterized by a very rapid separation with extraordinary resolution of peaks. This is achieved by the use of very fine particles and high pressure to maintain an adequate flow rate. Separation can be accomplished in a matter of minutes, or at most an hour. Moreover, only a very small volume of the sample is needed because the particles are so small and close-packed that the void volume is a very small fraction of the bed volume. Also, the concentration of the sample need not be very great because the bands are so narrow that there is very little dilution of the sample.
Retrovirus, adenovirus, adeno-associated virus, and herpes simplex virus are the most commonly used viruses in gene therapy (Robbins and Ghivizzani; 1998). It is contemplated in the present invention that the preparation of long-term stable adenovirus vectors that can be stored at or above refrigerated temperatures would be useful as gene therapy vectors. Viral particles must maintain their structural integrity to remain infective and biologically active for use as gene therapy vectors. Current virus formulations do not readily make it feasible to store or transport viral vector at or above refrigerated temperatures without significant loss of viral infectivity.
The present invention describes long-term stable adenovirus formulations that can be stored at 4° C. for periods up to 6 months. In one embodiment of the present invention, adenovirus preparations are formulated for lyophilization and long-term storage at 4° C. as freeze-dried adenovirus. In another embodiment, the adenovirus is prepared as a liquid formulation that is long-term stable at 4° C. An important aspect of both the lyophilized and liquid adenovirus formulations is the addition of at least one or more compounds that improve the long-term, storage stability of the adenovirus.
The term “compound” in the context of the present invention includes pharmaceutically acceptable carriers such as bulking agents, cryoprotectants, lyoprotectants, preservatives, solvents, solutes and any additional pharmaceutical agents well known in the art. Buffering agents and other types of pH control can also be added simultaneously in order to provide for maximum buffering capacity for the adenovirus formulation. For example, pH changes that deviate from physiological conditions often result in irreversible aggregation of proteins (Wetzel, 1992) and viral capsids (Misselwitz et al., 1995) due to complete or partial denaturation of the protein. Thus, buffering agents are particularly important for virus preparations that aggregate or denature at sub-optimal pH ranges.
1. Lyophilized Formulations
The formulation of lyophilized, long-term storage stable adenovirus in the present invention requires the presence of one or more excipients. More particularly, for optimal long-term stability of lyophilized adenovirus formulations, a bulking agent and one or more protectants are desirable. It is well known in the art that loss in virus infectivity often is directly related to denaturation, self association and aggregation of the viral particles (Misselwitz et al., 1995; Vanlandschoot et al., 1998; Sagrera et al., 1998; Lu et al., 1998). In fact, the E. coli heat shock proteins GroEL/GroES have been shown to both stabilize viral particles from denaturation and aggregation during high stress cellular conditions and to facilitate capsid assembly during non-stressed, normal cellular conditions (Polissi et al., 1995; Nakonechny and Teschke, 1998).
The use of bulking agents, cryoprotectants, lyoprotectants and salts in the present invention are included in the formulation of lyophilized adenovirus to improve long-term stability (i.e. infectivity) of the adenovirus freeze-dried products. The stabilizing effect of the cryoprotectant sucrose against irreversible denaturation and aggregation has been described previously as an excluded volume effect (Hall et al., 1995). Similarly, bulking agents, cryo- and lyoprotectants such as polyacrylamide gels, agaorse gels, dextran and polyethylene glycol (PEG) have demonstrated enhanced stabilities of proteins and nucleic acids in part by excluded volume effects (Fried and Bromberg, 1997; Vossen and Fried, 1997). The exact mechanistic details of excluded volume effects are still not clear. A currently accepted theory is that many of these compounds result in the preferential hydration of protein molecules (i.e. volume of exclusion), which tends to stabilize the native versus the denatured conformation of proteins, and therefore prevents aggregation. In addition, the presence of low concentrations of cosolvents (e.g., salts) result in charge screening of proteins and viral protein coats increasing their solubility in water.
The use of bulking agents, cryoprotectants, lyoprotectants and salts in the present invention are contemplated and demonstrated experimentally to improve the storage stability of lyophilized adenovirus products. In one embodiment, a bulking agent and protectants are combined with a buffer comprising adenovirus.
Bulking agents, cryoprotectants and lyoprotectants are well known in the art (Lueckel et al., 1998; Herman et al., 1994; Croyle et al., 1998; Corveleyn and Remon, 1996). Bulking agents considered in the present invention are mannitol, inositol, lactitol, xylitol, isomaltol, sorbitol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silcate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose, methylcellulose and other bulking agents well known in the art. Cryoprotectants considered are sucrose, dextrose, lactose, trehalose, glucose, maltose, niacinamide, creatinine, monosodium glutamate, dimethyl sulfoxide, sweet whey solids, as well as other known cryoprotectants. Lyoprotectants contemplated for use in the present invention are human serum albumin, bovine serum albumin, PEG, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 and Tween-80. Certain lyoprotectants are also classified as cryoprotectants and vice versa. For the purpose of the present invention, cryoprotectants and lyoprotectants are represented as independent classes of compounds. However, this classification is only for clarity of the invention and should not limit the person skilled in the art from using any excipient that stabilizes the adenovirus formulation. In other embodiments of the present invention, the term excipient encompasses bulking agents, cryo- and lyoprotectants. In certain embodiments, salts are included in the formulation in addition to the aforementioned excipients. The following salts are considered for use in the present invention MgCl2, MnCl2, CaCl2, ZnCl2, NaCl, and KCl, but should not preclude the use of other salts that improve stability of the adenovirus formulation.
In other embodiments of the invention, the lyophilized adenovirus formulation is dried in the presence of an inert gas or a combination of inert gasses. The purging of the lyophilization vessel with an inert gas or gasses, the presence of the inert gas or gasses during lyophilization of the adenovirus solution and during the capping of the lyophilization vial after the drying step, are contemplated to minimize the deleterious effects of O2. It is known that residual O2 leads to oxidation and degradation of proteins. It is contemplated that purging and capping of the freeze-dried adenovirus product improves the long-term storage stability of the adenovirus product. The use of antioxidants such as β-mercapto ethanol, DTT, citric acid and the like may also be considered for use in formulations.
An important aspect of the lyophilization process is a second drying cycle. The second drying cycle is at a temperature of 30° C. for at least 3.5 hours, which is demonstrated to reduce the residual moisture of the adenovirus freeze-dried product to less than 2% water immediately after drying. It is contemplated that the reduced residual moisture improves the long-term storage stability of the adenovirus freeze-dried product. Longer drying times up to 20 hours are thus contemplated to further reduce residual moisture.
2. Liquid Formulations
The formulation of liquid, long-term storage stable adenovirus in the present invention requires the presence of a polyol. A polyol is a polyhydric alcohol containing two or more hydroxyl groups. For optimal long-term stability of liquid adenovirus formulations in the present invention, glycerol is used. In particular embodiments of the invention, the presence 20% glycerol results in adenovirus stability (80% PFU/mL) for periods of time at least up to 6 months days when stored at 4° C.
Glycerol (glycerin) is one of the oldest and most widely used excipients in pharmaceutical products. It is a clear, colorless liquid which is miscible with water and alcohol. Glycerol is hygroscopic, stable to mild acidic and basic environments and can be sterilized at temperatures up to 150° C. It is well known as both a taste masking and cryoprotective agent, as well as an antimicrobial agent. It has good solubilizing power and is a commonly used solvent in parenteral formulations. It is considered to be one of the safest excipients used since it is metabolized to glucose, or to substances which are involved with triglyceride synthesis or glycolysis (Frank et al., 1981). It is a GRAS listed excipient and typically used at levels up to 50% in parenteral formulations.
The stabilizing effects of glycerol on protein structure is well known in the art (Hase et al., 1998; Juranville et al., 1998). Several studies indicate that glycerol has a similar effect of viral particles. For example, when competent Haemophilus influenza bacteria were exposed to purified phage and plated for transfectants, a 100-fold increase in transfectants was observed when 32% glycerol was present in the solution (Stuy, 1986) In yet another study, glycerol was demonstrated to preserve the integrity of vaccinia virus (Slonin and Roslerova, 1969).
Other polyols contemplated for use in the present invention are polyethylene glycol, propylene glycol, sorbitol, mannitol, and the like. Polyethylene glycols are polymers of ethylene oxide with the general formula:
HO—CH2—(CH2—O—CH2)n—CH2OH
where n represents the number of oxyethylene groups. The PEG's are designated by a numerical value, which is indicative of the average molecular weight for a given grade. Molecular weights below 600 are liquids, and molecular weights above 1000 are solids at room temperature. These polymers are readily soluble in water, which make them quite useful for parenteral dosage forms. Only PEG 400 and PEG 300 are utilized in parenteral products, typically at concentrations up to 30% v/v. These polymers are generally regarded as non-toxic and non-irritating. There are numerous reviews regarding the pharmaceutical and toxicological characteristics of these polyols (Smyth et al., 1950; Rowe and Wolf, 1982, Swarbrick and Boylan, 1990).
Propylene glycol, a dihydroxy alcohol, is one of the more common solvents encountered in pharmaceutical cosolvent formulations, for both parenteral and non-parenteral dosage forms. PG is generally regarded as non-toxic. It is more hygroscopic than glycerin, and has excellent solubilizing power for a wide variety of compounds. In addition, it has excellent bacteriocidal and preservative properties (Heine et al., 1950). PG is metabolized to carbon dioxide and water via lactic and pyruvic acid intermediates and, therefore, not prone to the severe toxicities.
Sorbitol and mannitol are hexahydric alcohols, consisting of white, crystalline powders, that are soluble in water. Both are commonly used excipients in pharmaceutical products with little or no toxicity associated, as approved by the FDA for food use. The mechanistics of sorbitol and mannitol protein and viral stabilization is still not completely understood. Current theories suggest at least part of the effect is osmotic diuretic (Vanholder, et al., 1984; de Rizzo, et al., 1988). The use of the polyols described above are considered exemplary, but should not limit the skilled artist from selecting other polyols that confer viral stability for liquid formulations.
It is also contemplated, in addition to a polyol in the liquid formulation, that one or possibly two excipients may also be included. Excipients considered for use in the present invention are inositol, lactitol, xylitol, isomaltol, gelatin, agar, pectin, casein, dried skim milk, dried whole milk, silcate, carboxypolymethylene, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methhylcellulose, methylcellulose, sucrose, dextrose, lactose, trehalose, glucose, maltose, niacinamide, creatinine, monosodium glutamate, dimethyl sulfoxide, sweet whey solids, human serum albumin, bovine serum albumin, glycine, arginine, proline, lysine, alanine, polyvinyl pyrrolidine, polyvinyl alcohol, polydextran, maltodextrins, hydroxypropyl-beta-cyclodextrin, partially hydrolysed starches, Tween-20 and Tween-80. The choice of a particular excipient is dependent in some instances on the desired properties of the viral formulation.
In particular embodiments, dimethyl sulfoxide (DMSO) is contemplated for use in the present invention. DMSO has been demonstrated to enhance the infectivity of adenovirus preparations by increasing the efficiency of gene transfer (Chikada and Jones, 1999). For example, the infectivity of adenovirus type 2 DNA in 293 cells was increased up to five-fold by the brief treatment of cell monolayers with 25% DMSO (Chinnadurai et al., 1978) The stabilization of virus particles via DMSO also has been reported (Wallis and Melnick, 1968). The present inventors demonstrate that the intratumoral administration of Ad-p53 is improved when DMSO is added to 5 or 10% (see
Thus in particular embodiments, an adenoviral formulation according to the present invention may also contain DMSO. The concentration for intratumoral administration may contain from about 2% to 67% DMSO, preferably from about 5% to 20%. The concentration for intravesical administration may contain from about 2% to 67% DMSO, preferably from about 20% to 50%. The concentration for topical administration may contain from about 2% to 67% DMSO, preferably from about 10% to 40%. The concentration for intra-articular administration may contain from about 2% to 67% DMSO, preferably, from about 5% to 40%. The concentration for systemic administration may contain from about 2% to 75% DMSO, preferably from about 50% to 67%.
Adenovirus polyol formulations of the invention may future comprise a polyoxamer, such as Polyoxamer 407, at concentrations of from about 0.5% to 20%, preferably from about 10% to 20%. The formulation storage stable adenovirus may also contain from about 5% to 40% dimethylacetamide, preferably from about 10% to 25%, Or it may contain from about 10% to 50% of a polyethylene glycol, such as polyethylene glycol 400, preferably from about 15% to 50%. Of course, the formulation of said adenovirus also may contain combinations of the above components.
The present invention employs, in one example, adenoviral infection of cells in order to generate therapeutically significant vectors. Typically, the virus will simply be exposed to the appropriate host cell under physiologic conditions, permitting uptake of the virus. Though adenovirus is exemplified, the present methods may be advantageously employed with other viral vectors, as discussed below.
1. Viral Infection
a. Adenovirus
One method for delivery of the recombinant DNA involves the use of an adenovirus expression vector. Although adenovirus vectors are known to have a low capacity for integration into genomic DNA, this feature is counterbalanced by the high efficiency of gene transfer afforded by these vectors. “Adenovirus expression vector” is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to ultimately express a recombinant gene construct that has been cloned therein.
The vector comprises a genetically engineered form of adenovirus. Knowledge of the genetic organization or adenovirus, a 36 kb, linear, double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus and Horwitz, 1992). In contrast to retrovirus, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification.
Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off (Renan, 1990). The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNA's issued from this promoter possess a 5′-tripartite leader (TPL) sequence which makes them preferred mRNA's for translation.
In a current system, recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of virus from an individual plaque and examine its genomic structure.
Generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses E1 proteins (Graham et al., 1977). Since the E3 region is dispensable from the adenovirus genome (Jones and Shenk, 1978), the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the E1, the D3 or both regions (Graham and Prevec, 1991). In nature, adenovirus can package approximately 105% of the wild-type genome (Ghosh-Choudhury et al., 1987), providing capacity for about 2 extra kb of DNA. Combined with the approximately 5.5 kb of DNA that is replaceable in the E1 and E3 regions, the maximum capacity of the current adenovirus vector is under 7.5 kb, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone.
Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, e.g., Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, the preferred helper cell line is 293.
Racher et al. (1995) have disclosed improved methods for culturing 293 cells and propagating adenovirus. In one format, natural cell aggregates are grown by inoculating individual cells into 1 liter siliconized spinner flasks (Techne, Cambridge, UK) containing 100-200 ml of medium. Following stirring at 40 rpm, the cell viability is estimated with trypan blue. In another format, Fibra-Cel microcarriers (Bibby Sterlin, Stone, UK) (5 g/l) is employed as follows. A cell inoculum, resuspended in 5 ml of medium, is added to the carrier (50 ml) in a 250 ml Erlenmeyer flask and left stationary, with occasional agitation, for 1 to 4 h. The medium is then replaced with 50 ml of fresh medium and shaking initiated. For virus production, cells are allowed to grow to about 80% confluence, after which time the medium is replaced (to 25% of the final volume) and adenovirus added at an MOI of 0.05. Cultures are left stationary overnight, following which the volume is increased to 100% and shaking commenced for another 72 h.
Other than the requirement that the adenovirus vector be replication defective, or at least conditionally defective, the nature of the adenovirus vector is not believed to be crucial to the successful practice of the invention. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain the conditional replication-defective adenovirus vector for use in the present invention. This is because Adenovirus type 5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector.
As stated above, the typical vector according to the present invention is replication defective and will not have an adenovirus E1 region. Thus, it will be most convenient to introduce the transforming construct at the position from which the E1-coding sequences have been removed. However, the position of insertion of the construct within the adenovirus sequences is not critical to the invention. The polynucleotide encoding the gene of interest may also be inserted in lieu of the deleted E3 region in E3 replacement vectors as described by Karlsson et al. (1986) or in the E4 region where a helper cell line or helper virus complements the E4 defect.
Adenovirus growth and manipulation is known to those of skill in the art, and exhibits broad host range in vitro and in vivo. This group of viruses can be obtained in high titers, e.g., 109-1011 plaque-forming units per ml, and they are highly infective. The life cycle of adenovirus does not require integration into the host cell genome. The foreign genes delivered by adenovirus vectors are episomal and, therefore, have low genotoxicity to host cells. No side effects have been reported in studies of vaccination with wild-type adenovirus (Couch et al., 1963; Top et al., 1971), demonstrating their safety and therapeutic potential as in vivo gene transfer vectors.
Adenovirus vectors have been used in eukaryotic gene expression (Levrero et al., 1991; Gomez-Foix et al., 1992) and vaccine development (Grunhaus and Horwitz, 1992; Graham and Prevec, 1992). Adenoviral vectors also have been described for treatment of certain types of cancers (U.S. Pat. No. 5,789,244, specifically incorporated herein by reference in its entirety). Animal studies have suggested that recombinant adenovirus could be used for gene therapy (Stratford-Perricaudet and Perricaudet, 1991; Stratford-Perricaudet et al., 1990; Rich et al., 1993). Studies in administering recombinant adenovirus to different tissues include trachea instillation (Rosenfeld et al., 1991; Rosenfeld et al., 1992), muscle injection (Ragot et al., 1993), peripheral intravenous injections (Herz and Gerard, 1993) and stereotactic inoculation into the brain (Le Gal La Salle et al., 1993).
b. Retrovirus
The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene contains a signal for packaging of the genome into virions. Two long terminal repeat (LTR) sequences are present at the 5′ and 3′ ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990).
In order to construct a retroviral vector, a nucleic acid encoding a gene of interest is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann et al., 1983). When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into this cell line (by calcium phosphate precipitation for example), the packaging sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann et al., 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind et al., 1975).
Concern with the use of defective retrovirus vectors is the potential appearance of wild-type replication-competent virus in the packaging cells. This can result from recombination events in which the intact sequence from the recombinant virus inserts upstream from the gag, pol, env sequence integrated in the host cell genome. However, new packaging cell lines are now available that should greatly decrease the likelihood of recombination (Markowitz et al., 1988; Hersdorffer et al., 1990).
c. Adeno-Associated Virus
Adeno-associated virus (AAV) is an attractive vector system for use in the present invention as it has a high frequency of integration and it can infect nondividing cells, thus making it useful for delivery of genes into mammalian cells in tissue culture (Muzyczka, 1992). AAV has a broad host range for infectivity (Tratschin, et al., 1984; Laughlin, et al., 1986; Lebkowski, et al., 1988; McLaughlin, et al., 1988), which means it is applicable for use with the present invention. Details concerning the generation and use of rAAV vectors are described in U.S. Pat. No. 5,139,941 and U.S. Pat. No. 4,797,368, each incorporated herein by reference.
Studies demonstrating the use of AAV in gene delivery include LaFace et al. (1988); Zhou et al. (1993); Flotte et al. (1993); and Walsh et al. (1994). Recombinant AAV vectors have been used successfully for in vitro and in vivo transduction of marker genes (Kaplitt et al., 1994; Lebkowski et al., 1988; Samulski et al., 1989; Shelling and Smith, 1994; Yoder et al., 1994; Zhou et al., 1994; Hermonat and Muzyczka, 1984; Tratschin et al., 1985; McLaughlin et al., 1988) and genes involved in human diseases (Flotte et al., 1992; Luo et al., 1994; Ohi et al., 1990; Walsh et al., 1994; Wei et al., 1994). Recently, an AAV vector has been approved for phase I human trials for the treatment of cystic fibrosis.
AAV is a dependent parvovirus in that it requires coinfection with another virus (either adenovirus or a member of the herpes virus family) to undergo a productive infection in cultured cells (Muzyczka, 1992). In the absence of coinfection with helper virus, the wild-type AAV genome integrates through its ends into human chromosome 19 where it resides in a latent state as a provirus (Kotin et al., 1990; Samulski et al., 1991). rAAV, however, is not restricted to chromosome 19 for integration unless the AAV Rep protein is also expressed (Shelling and Smith, 1994). When a cell carrying an AAV provirus is superinfected with a helper virus, the AAV genome is “rescued” from the chromosome or from a recombinant plasmid, and a normal productive infection is established (Samulski et al., 1989; McLaughlin et al., 1988; Kotin et al., 1990; Muzyczka, 1992).
Typically, recombinant AAV (rAAV) virus is made by cotransfecting a plasmid containing the gene of interest flanked by the two AAV terminal repeats (McLaughlin et al., 1988; Samulski et al., 1989; each incorporated herein by reference) and an expression plasmid containing the wild-type AAV coding sequences without the terminal repeats, for example pIM45 (McCarty et al., 1991; incorporated herein by reference). The cells are also infected or transfected with adenovirus or plasmids carrying the adenovirus genes required for AAV helper function. rAAV virus stocks made in such fashion are contaminated with adenovirus which must be physically separated from the rAAV particles (for example, by cesium chloride density centrifugation). Alternatively, adenovirus vectors containing the AAV coding regions or cell lines containing the AAV coding regions and some or all of the adenovirus helper genes could be used (Yang et al., 1994a; Clark et al., 1995). Cell lines carrying the rAAV DNA as an integrated provirus can also be used (Flotte et al., 1995).
d. Other Viral Vectors
Other viral vectors may be employed as constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al., 1988) and herpesviruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al., 1988; Horwich et al., 1990).
With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. In vitro studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite the deletion of up to 80% of its genome (Horwich et al., 1990). This suggested that large portions of the genome could be replaced with foreign genetic material. Chang et al. recently introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding sequences. It was cotransfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang et al., 1991).
Also contemplated for use in the present invention is a fairly new class of viruses termed oncolytic virus (Pennisi, 1998). Some of the viruses included in this group are reovirus, the genetically modified adenovirus OYNX-015 and CN706. These oncolytic viruses, which have not been genetically altered to prevent their replication, destroy certain types of cancer cells by multiplying and spreading, killing only the cancer cells. Each of the above oncolytic viruses are proposed to operate via different pathways involved in cancers.
For example, human reovirus requires an activated Ras signaling pathway for infection of cultured cells. Thus, in certain tumors with an overactive ras gene, reovirus readily replicates. In a study on reovirus, severe combined immune deficient mice bearing tumors established from v-erbB-transformed murine NIH 3T3 cells or human U87 glioblastoma cells were treated with the virus. A single intratumoral injection of virus resulted in regression of tumors in 65% to 80% of the mice. Treatment of immune-competent C3H mice bearing tumors established from a ras-transformed C3H-10T1/2 cells also resulted in tumor regression, although a series of injections were required (Coffey et al., 1998)
2. Vectors and Regulatory Signals
Vectors of the present invention are designed, primarily, to transform cells with a gene under the control of regulated eukaryotic promoters (i.e., inducible, repressable, tissue specific). Also, the vectors usually will contain a selectable marker if, for no other reason, to facilitate their production in vitro. However, selectable markers may play an important role in producing recombinant cells and thus a discussion of promoters is useful here. Table 2 and Table 3 below, list inducible promoter elements and enhancer elements, respectively.
TABLE 2
Inducible Elements
Element
Inducer
References
MT II
Phorbol Ester (TFA)
Palmiter et al., 1982; Haslinger and
Heavy metals
Karin, 1985; Searle et al., 1985;
Stuart et al., 1985; Imagawa et al.,
1987; Karin ®, 1987; Angel et al.,
1987b; McNeall et al., 1989
MMTV (mouse
Glucocorticoids
Huang et al., 1981; Lee et al., 1981;
mammary tumor virus)
Majors and Varmus, 1983;
Chandler et al., 1983; Lee et al.,
1984; Fonta et al., 1985; Sakai
et al., 1986
β-Interferon
poly(rI)X
Tavernier et al., 1983
poly(rc)
Adenovirus 5 E2
Ela
Imperiale and Nevins, 1984
Collagenase
Phorbol Ester (TPA)
Angle et al., 1987a
Stromelysin
Phorbol Ester (TPA)
Angle et al., 1987b
SV40
Phorbol Ester (TFA)
Angel et al., 1987b
Murine MX Gene
Interferon, Newcastle
Disease Virus
GRP78 Gene
A23187
Resendez et al., 1988
α-2-Macroglobulin
IL-6
Kunz et al., 1989
Vimentin
Serum
Rittling et al., 1989
MHC Class I Gene H-2κb
Interferon
Blanar et al., 1989
HSP70
Ela, SV40 Large T
Taylor et al., 1989; Taylor and
Antigen
Kingston, 1990a, b
Proliferin
Phorbol Ester-TPA
Mordacq and Linzer, 1989
Tumor Necrosis Factor
FMA
Hensel et al., 1989
Thyroid Stimulating
Thyroid Hormone
Chatterjee et al., 1989
Hormone α Gene
TABLE 3
Other Promoter/Enhancer Elements
Promoter/Enhancer
References
Immunoglobulin Heavy Chain
Hanerji et al., 1983; Gilles et al., 1983; Grosschedl and
Baltimore, 1985; Atchinson and Perry, 1986, 1987; Imler
et al., 1987; Weinberger et al., 1988; Kiledjian et al.,
1988; Porton et al., 1990
Immunoglobulin Light Chain
Queen and Baltimore, 1983; Picard and Schaffner, 1984
T-Cell Receptor
Luria et al., 1987, Winoto and Baltimore, 1989; Redondo
et al., 1990
HLA DQ α and DQ β
Sullivan and Peterlin, 1987
β-Interferon
Goodbourn et al., 1986; Fujita et al., 1987; Goodbourn
and Maniatis, 1985
Interleukin-2
Greene et al., 1989
Interleukin-2 Receptor
Greene et al., 1989; Lin et al., 1990
MHC Class II 5
Koch et al., 1989
MHC Class II HLA-DRα
Sherman et al., 1989
β-Actin
Kawamoto et al., 1988; Ng et al., 1989
Muscle Creatine Kinase
Jaynes et al., 1988; Horlick and Benfield, 1989; Johnson
et al., 1989a
Prealbumin (Transthyretin)
Costa et al., 1988
Elastase I
Omitz et al., 1987
Metallothionein
Karin et al., 1987; Culotta and Hamer, 1989
Collagenase
Pinkert et al., 1987; Angel et al., 1987
Albumin Gene
Pinkert et al., 1987, Tronche et al., 1989, 1990
α-Fetoprotein
Godbout et al., 1988; Campere and Tilghman, 1989
t-Globin
Bodine and Ley, 1987; Perez-Stable and Constantini,
1990
β-Globin
Trudel and Constantini, 1987
e-fos
Cohen et al., 1987
c-HA-ras
Triesman, 1986; Deschamps et al., 1985
Insulin
Edlund et al., 1985
Neural Cell Adhesion Molecule
Hirsch et al., 1990
(NCAM)
a1-Antitrypain
Latimer et al., 1990
H2B (TH2B) Histone
Hwang et al., 1990
Mouse or Type I Collagen
Ripe et al., 1989
Glucose-Regulated Proteins
Chang et al., 1989
(GRP94 and GRP78)
Rat Growth Hormone
Larsen et al., 1986
Human Serum Amyloid A (SAA)
Edbrooke et al., 1989
Troponin I (TN I)
Yutzey et al., 1989
Platelet-Derived Growth Factor
Pech et al., 1989
Duchenne Muscular Dystrophy
Klamut et al., 1990
SV40
Banerji et al., 1981; Moreau et al., 1981; Sleigh and
Lockett, 1985; Firak and Subramanian, 1986; Herr and
Clarke, 1986; Imbra and Karin, 1986; Kadesch and Berg,
1986; Wang and Calame, 1986; Ondek et al., 1987; Kuhl
et al., 1987 Schaffner et al., 1988
Polyoma
Swartzendruber and Lehman, 1975; Vasseur et al., 1980;
Katinka et al., 1980, 1981; Tyndell et al., 1981; Dandolo
et al., 1983; deVilliers et al., 1984; Hen et al., 1986;
Satake et al., 1988; Campbell and Villarreal, 1988
Retroviruses
Kriegler and Botchan, 1982, 1983; Levinson et al., 1982;
Kriegler et al., 1983, 1984a, b, 1988; Bosze et al., 1986;
Miksicek et al., 1986; Celander and Haseltine, 1987;
Thiesen et al., 1988; Celander et al., 1988; Chol et al.,
1988; Reisman and Rotter, 1989
Papilloma Virus
Campo et al., 1983; Lusky et al., 1983; Spandidos and
Wilkie, 1983; Spalholz et al., 1985; Lusky and Botchan,
1986; Cripe et al., 1987; Gloss et al., 1987; Hirochika
et al., 1987, Stephens and Hentschel, 1987; Glue et al.,
1988
Hepatitis B Virus
Bulla and Siddiqui, 1986; Jameel and Siddiqui, 1986;
Shaul and Ben-Levy, 1987; Spandau and Lee, 1988
Human Immunodeficiency Virus
Muesing et al., 1987; Hauber and Cullan, 1988;
Jakobovits et al., 1988; Feng and Holland, 1988; Takebe
et al., 1988; Rowen et al., 1988; Berkhout et al., 1989;
Laspia et al., 1989; Sharp and Marciniak, 1989; Braddock
et al., 1989
Cytomegalovirus
Weber et al., 1984; Boshart et al., 1985; Foecking and
Hofstetter, 1986
Gibbon Ape Leukemia Virus
Holbrook et al., 1987; Quinn et al., 1989
Another signal that may prove useful is a polyadenylation signal (hGH, BGH, SV40).
The use of internal ribosome binding sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5′-methylated cap-dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow, 1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message.
As discussed above, in certain embodiments of the invention, a cell may be identified and selected in vitro or in vivo by including a marker in the expression construct. Such markers confer an identifiable change to the cell permitting easy identification of cells containing the expression construct. Usually, the inclusion of a drug selection marker aids in cloning and in the selection of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin, tetracycline and histidinol are useful selectable markers. Alternatively, enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be employed.
The promoters and enhancers that control the transcription of protein encoding genes in eukaryotic cells are composed of multiple genetic elements. The cellular machinery is able to gather and integrate the regulatory information conveyed by each element, allowing different genes to evolve distinct, often complex patterns of transcriptional regulation.
The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator proteins.
At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV 40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.
Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between elements is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.
Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA. This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation. Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.
The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Aside from this operational distinction, enhancers and promoters are very similar entities.
Promoters and enhancers have the same general function of activating transcription in the cell. They are often overlapping and contiguous, often seeming to have a very similar modular organization. Taken together, these considerations suggest that enhancers and promoters are homologous entities and that the transcriptional activator proteins bound to these sequences may interact with the cellular transcriptional machinery in fundamentally the same way.
In any event, it will be understood that promoters are DNA elements which when positioned functionally upstream of a gene leads to the expression of that gene. Most transgene constructs of the present invention are functionally positioned downstream of a promoter element.
In certain embodiments, the present invention further involves the manipulation of viral vectors. Such methods involve the use of a vector construct containing, for example, a heterologous DNA encoding a gene of interest and a means for its expression, replicating the vector in an appropriate helper cell, obtaining viral particles produced therefrom, and infecting cells with the recombinant virus particles. The gene could simply encode a protein for which large quantities of the protein are desired, i.e., large scale in vitro production methods. Alternatively, the gene could be a therapeutic gene, for example to treat cancer cells, to express immunomodulatory genes to fight viral infections, or to replace a gene's function as a result of a genetic defect. In the context of the gene therapy vector, the gene will be a heterologous DNA, meant to include DNA derived from a source other than the viral genome which provides the backbone of the vector. Finally, the virus may act as a live viral vaccine and express an antigen of interest for the production of antibodies they are against. The gene may be derived from a prokaryotic or eukaryotic source such as a bacterium, a virus, a yeast, a parasite, a plant, or even an animal. The heterologous DNA also may be derived from more than one source, i.e., a multigene construct or a fusion protein. The heterologous DNA may also include a regulatory sequence which may be derived from one source and the gene from a different source.
1. Therapeutic Genes
p53 currently is recognized as a tumor suppressor gene (Montenarh, 1992). High levels of mutant p53 have been found in many cells transformed by chemical carcinogenesis, ultraviolet radiation, and several viruses, including SV40. The p53 gene is a frequent target of mutational inactivation in a wide variety of human tumors and is already documented to be the most frequently-mutated gene in common human cancers (Mercer, 1992). It is mutated in over 50% of human NSCLC (Hollestein et al., 1991) and in a wide spectrum of other tumors.
The p53 gene encodes a 393-amino-acid phosphoprotein that can form complexes with host proteins such as large-T antigen and E1B. The protein is found in normal tissues and cells, but at concentrations which are generally minute by comparison with transformed cells or tumor tissue. Interestingly, wild-type p53 appears to be important in regulating cell growth and division. Overexpression of wild-type p53 has been shown in some cases to be anti-proliferative in human tumor cell lines. Thus; p53 can act as a negative regulator of cell growth (Weinberg, 1991) and may directly suppress uncontrolled cell growth or directly or indirectly activate genes that suppress this growth. Thus, absence or inactivation of wild-type p53 may contribute to transformation. However, some studies indicate that the presence of mutant p53 may be necessary for full expression of the transforming potential of the gene.
Wild-type p53 is recognized as an important growth regulator in many cell types. Missense mutations are common for the p53 gene and are known to occur in at least 30 distinct codons, often creating dominant alleles that produce shifts in cell phenotype without a reduction to homozygosity. Additionally, many of these dominant negative alleles appear to be tolerated in the organism and passed on in the germ line. Various mutant alleles appear to range from minimally dysfunctional to strongly penetrant, dominant negative alleles (Weinberg, 1991).
Casey and colleagues have reported that transfection of DNA encoding wild-type p53 into two human breast cancer cell lines restores growth suppression control in such cells (Casey et al., 1991). A similar effect has also been demonstrated on transfection of wild-type, but not mutant, p53 into human lung cancer cell lines (Takahasi et al., 1992). p53 appears dominant over the mutant gene and will select against proliferation when transfected into cells with the mutant gene. Normal expression of the transfected p53 is not detrimental to normal cells with endogenous wild-type p53. Thus, such constructs might be taken up by normal cells without adverse effects. It is thus proposed that the treatment of p53-associated cancers with wild-type p53 expression constructs will reduce the number of malignant cells or their growth rate. Furthermore, recent studies suggest that some p53 wild-type tumors are also sensitive to the effects of exogenous p53 expression.
The major transitions of the eukaryotic cell cycle are triggered by cyclin-dependent kinases, or CDK's. One CDK, cyclin-dependent kinase 4 (CDK4), regulates progression through the G1 phase. The activity of this enzyme may be to phosphorylate Rb at late G1. The activity of CDK4 is controlled by an activating subunit, D-type cyclin, and by an inhibitory subunit, e.g. p16INK4, which has been biochemically characterized as a protein that specifically binds to and inhibits CDK4, and thus may regulate Rb phosphorylation (Serrano et al., 1993; Serrano et al., 1995). Since the p16INK4 protein is a CDK4 inhibitor (Serrano, 1993), deletion of this gene may increase the activity of CDK4, resulting in hyperphosphorylation of the Rb protein. p16 also is known to regulate the function of CDK6.
p16INK4 belongs to a newly described class of CDK-inhibitory proteins that also includes p16B, p2WAF1,CIPI,SD11 and p27KIP1. The p16INK4 gene maps to 9p21, a chromosome region frequently deleted in many tumor types. Homozygous deletions and mutations of the p16INK4 gene are frequent in human tumor cell lines. This evidence suggests that the p16INK4 gene is a tumor suppressor gene. This interpretation has been challenged, however, by the observation that the frequency of the p16INK4 gene alterations is much lower in primary uncultured tumors than in cultured cell lines (Caldas et al., 1994; Cheng et al., 1994; Hussussian et al., 1994; Kamb et al., 1994a; Kamb et al., 1994b; Mori et al., 1994; Okamoto et al., 1994; Nobori et al., 1995; Orlow et al., 1994; Arap et al., 1995). Restoration of wild-type p16INK4 function by transfection with a plasmid expression vector reduced colony formation by some human cancer cell lines (Okamoto, 1994; Arap, 1995).
C-CAM is expressed in virtually all epithelial cells (Odin and Obrink, 1987). C-CAM, with an apparent molecular weight of 105 kD, was originally isolated from the plasma membrane of the rat hepatocyte by its reaction with specific antibodies that neutralize cell aggregation (Obrink, 1991). Recent studies indicate that, structurally, C-CAM belongs to the immunoglobulin (Ig) superfamily and its sequence is highly homologous to carcinoembryonic antigen (CEA) (Lin and Guidotti, 1989). Using a baculovirus expression system, Cheung et al. (1993a; 1993b and 1993c) demonstrated that the first Ig domain of C-CAM is critical for cell adhesion activity.
Cell adhesion molecules, or CAMs are known to be involved in a complex network of molecular interactions that regulate organ development and cell differentiation (Edelman, 1985). Recent data indicate that aberrant expression of CAMs may be involved in the tumorigenesis of several neoplasms; for example, decreased expression of E-cadherin, which is predominantly expressed in epithelial cells, is associated with the progression of several kinds of neoplasms (Edelman and Crossin, 1991; Frixen et al., 1991; Bussemakers et al., 1992; Matsura et al., 1992; Umbas et al., 1992). Also, Giancotti and Ruoslahti (1990) demonstrated that increasing expression of α5β1 integrin by gene transfer can reduce tumorigenicity of Chinese hamster ovary cells in vivo. CAM now has been shown to suppress tumor growth in vitro and in vivo.
Other tumor suppressors that may be employed according to the present invention include RB, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, zac1, p73, BRCA1, VHL, FCC, MMAC1, MCC, p16, p21, p57, C-CAM, p27 and BRCA2. Inducers of apoptosis, such as Bax, Bak, Bcl-Xs, Bik, Bid, Harakiri, Ad E1B, Bad and ICE-CED3 proteases, similarly could find use according to the present invention.
Various enzyme genes are of interest according to the present invention. Such enzymes include cytosine deaminase, hypoxanthine-guanine phosphoribosyltransferase, galactose-1-phosphate uridyltransferase, phenylalanine hydroxylase, glucocerbrosidase, sphingomyelinase, α-L-iduronidase, glucose-6-phosphate dehydrogenase, HSV thymidine kinase and human thymidine kinase.
Hormones are another group of gene that may be used in the vectors described herein. Included are growth hormone, prolactin, placental lactogen, luteinizing hormone, follicle-stimulating hormone, chorionic gonadotropin, thyroid-stimulating hormone, leptin, adrenocorticotropin (ACTH), angiotensin I and II, β-endorphin, β-melanocyte stimulating hormone (β-MSH), cholecystokinin, endothelin I, galanin, gastric inhibitory peptide (GIP), glucagon, insulin, lipotropins, neurophysins, somatostatin, calcitonin, calcitonin gene related peptide (CGRP), β-calcitonin gene related peptide, hypercalcemia of malignancy factor (1-40), parathyroid hormone-related protein (107-139) (PTH-rP), parathyroid hormone-related protein (107-111) (PTH-rP), glucagon-like peptide (GLP-1), pancreastatin, pancreatic peptide, peptide YY, PHM, secretin, vasoactive intestinal peptide (VIP), oxytocin, vasopressin (AVP), vasotocin, enkephalinamide, metorphinamide, alpha melanocyte stimulating hormone (alpha-MSH), atrial natriuretic factor (5-28) (ANF), amylin, amyloid P component (SAP-1), corticotropin releasing hormone (CRH), growth hormone releasing factor (GHRH), luteinizing hormone-releasing hormone (LHRH), neuropeptide Y, substance K (neurokinin A), substance P and thyrotropin releasing hormone (TRH).
Other classes of genes that are contemplated to be inserted into the vectors of the present invention include interleukins and cytokines. Interleukin 1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 IL-12, GM-CSF and G-CSF.
Examples of diseases for which the present viral vector would be useful include, but are not limited to, adenosine deaminase deficiency, human blood clotting factor IX deficiency in hemophilia B, and cystic fibrosis, which would involve the replacement of the cystic fibrosis transmembrane receptor gene. The vectors embodied in the present invention could also be used for treatment of hyperproliferative disorders such as rheumatoid arthritis or restenosis by transfer of genes encoding angiogenesis inhibitors or cell cycle inhibitors. Transfer of prodrug activators such as the HSV-TK gene can be also be used in the treatment of hyperploiferative disorders, including cancer.
2. Antisense Constructs
Oncogenes such as ras, myc, neu, raf erb, src, fms, jun, trk, ret, gsp, hst, bcl and abl also are suitable targets. However, for therapeutic benefit, these oncogenes would be expressed as an antisense nucleic acid, so as to inhibit the expression of the oncogene. The term “antisense nucleic acid” is intended to refer to the oligonucleotides complementary to the base sequences of oncogene-encoding DNA and RNA. Antisense oligonucleotides, when introduced into a target cell, specifically bind to their target nucleic acid and interfere with transcription, RNA processing, transport and/or translation. Targeting double-stranded (ds) DNA with oligonucleotide leads to triple-helix formation; targeting RNA will lead to double-helix formation.
Antisense constructs may be designed to bind to the promoter and other control regions, exons, introns or even exon-intron boundaries of a gene. Antisense RNA constructs, or DNA encoding such antisense RNAs, may be employed to inhibit gene transcription or translation or both within a host cell, either in vitro or in vivo, such as within a host animal, including a human subject. Nucleic acid sequences comprising “complementary nucleotides” are those which are capable of base-pairing according to the standard Watson-Crick complementarity rules. That is, that the larger purines will base pair with the smaller pyrimidines to form only combinations of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T), in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA.
As used herein, the terms “complementary” or “antisense sequences” mean nucleic acid sequences that are substantially complementary over their entire length and have very few base mismatches. For example, nucleic acid sequences of fifteen bases in length may be termed complementary when they have a complementary nucleotide at thirteen or fourteen positions with only single or double mismatches. Naturally, nucleic acid sequences which are “completely complementary” will be nucleic acid sequences which are entirely complementary throughout their entire length and have no base mismatches.
While all or part of the gene sequence may be employed in the context of antisense construction, statistically, any sequence 17 bases long should occur only once in the human genome and, therefore, suffice to specify a unique target sequence. Although shorter oligomers are easier to make and increase in vivo accessibility, numerous other factors are involved in determining the specificity of hybridization. Both binding affinity and sequence specificity of an oligonucleotide to its complementary target increases with increasing length. It is contemplated that oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more base pairs will be used. One can readily determine whether a given antisense nucleic acid is effective at targeting of the corresponding host cell gene simply by testing the constructs in vitro to determine whether the endogenous gene's function is affected or whether the expression of related genes having complementary sequences is affected.
In certain embodiments, one may wish to employ antisense constructs which include other elements, for example, those which include C-5 propyne pyrimidines. Oligonucleotides which contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and to be potent antisense inhibitors of gene expression (Wagner et al., 1993).
As an alternative to targeted antisense delivery, targeted ribozymes may be used. The term “ribozyme” refers to an RNA-based enzyme capable of targeting and cleaving particular base sequences in oncogene DNA and RNA. Ribozymes can either be targeted directly to cells, in the form of RNA oligo-nucleotides incorporating ribozyme sequences, or introduced into the cell as an expression construct encoding the desired ribozymal RNA. Ribozymes may be used and applied in much the same way as described for antisense nucleic acids.
3. Antigens for Vaccines
Other therapeutics genes might include genes encoding antigens such as viral antigens, bacterial antigens, fungal antigens or parasitic antigens. Viruses include picornavirus, coronavirus, togavirus, flavirviru, rhabdovirus, paramyxovirus, orthomyxovirus, bunyavirus, arenvirus, reovirus, retrovirus, papovavirus, parvovirus, herpesvirus, poxvirus, hepadnavirus, and spongiform virus. Preferred viral targets include influenza, herpes simplex virus 1 and 2, measles, small pox, polio or HIV. Pathogens include trypanosomes, tapeworms, roundworms, helminths. Also, tumor markers, such as fetal antigen or prostate specific antigen, may be targeted in this manner. Preferred examples include HIV env proteins and hepatitis B surface antigen. Administration of a vector according to the present invention for vaccination purposes would require that the vector-associated antigens be sufficiently non-immunogenic to enable long term expression of the transgene, for which a strong immune response would be desired. Preferably, vaccination of an individual would only be required infrequently, such as yearly or biennially, and provide long term immunologic protection against the infectious agent.
4. Control Regions
In order for the viral vector to effect expression of a transcript encoding a therapeutic gene, the polynucleotide encoding the therapeutic gene will be under the transcriptional control of a promoter and a polyadenylation signal. A “promoter” refers to a DNA sequence recognized by the synthetic machinery of the host cell, or introduced synthetic machinery, that is required to initiate the specific transcription of a gene. A polyadenylation signal refers to a DNA sequence recognized by the synthetic machinery of the host cell, or introduced synthetic machinery, that is required to direct the addition of a series of nucleotides on the end of the mRNA transcript for proper processing and trafficking of the transcript out of the nucleus into the cytoplasm for translation. The phrase “under transcriptional control” means that the promoter is in the correct location in relation to the polynucleotide to control RNA polymerase initiation and expression of the polynucleotide.
The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work; have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.
At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.
Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription.
In certain embodiments, the present invention also concerns formulations of a viral composition for administration to a mammal. It will also be understood that, if desired, the viral compositions disclosed herein may be administered in combination with other agents as well, such as, e.g., various pharmaceutically-active agents. As long as the compositions do not cause a significant adverse effect upon contact with the target cells or host tissues, there is virtually no limit to other components which may also be included.
The formulation of pharmaceutically-acceptable excipients and carrier solutions are well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including e.g., oral, parenteral, intravenous, intranasal, and intramuscular administration and formulation.
1. Injectable Compositions and Delivery
The pharmaceutical compositions disclosed herein may be administered parenterally, intravenously, intramuscularly, or even intraperitoneally as described in U.S. Pat. No. 5,543,158; U.S. Pat. No. 5,641,515 and U.S. Pat. No. 5,399,363 (each specifically incorporated herein by reference in its entirety). Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
Typically, these formulations may contain at least about 0.1% of the active compound or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Pat. No. 5,466,468, specifically incorporated herein by reference in its entirety). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial ad antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.
Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
The compositions disclosed herein may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.
As used herein, “carrier” includes any and all solvents, dispersion media, vehicles coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
The phrase “pharmaceutically-acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified.
2. Oral Compositions and Delivery
Alternatively, the pharmaceutical compositions disclosed herein may be delivered via oral administration to an animal, and as such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (Mathiowitz et al., 1997; Hwang et al., 1998; U.S. Pat. No. 5,641,515; U.S. Pat. No. 5,580,579 and U.S. Pat. No. 5,792,451, each specifically incorporated herein by reference in its entirety). The tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup of elixir may contain the active compounds sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations.
For oral administration the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, or sublingual orally-administered formulation. For example, a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the active ingredient may be incorporated into an oral solution such as those containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, including: gels, pastes, powders and slurries, or added in a therapeutically effective amount to a paste dentifrice that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants, or alternatively fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.
3. Nasal Delivery
The administration of agonist pharmaceutical compositions by intranasal sprays, inhalation, and/or other aerosol delivery vehicles is also considered. Methods for delivering genes, nucleic acids, and peptide compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U.S. Pat. No. 5,756,353 and U.S. Pat. No. 5,804,212 (each specifically incorporated herein by reference in its entirety), and delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725,871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts. Likewise, transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Pat. No. 5,780,045 (specifically incorporated herein by reference in its entirety).
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Lyophilizer
A Dura-stop μp lyophilizer (FTSsystems) with in process sample retrieving device was used. The lyophilizer is equipped with both thermocouple vacuum gauge and capacitance manometer for vacuum measurement. Condenser temperature is programmed to reach to −80° C. Vials were stoppered at the end of each run with a build-in mechanical stoppering device.
Residual Moisture Measurement
Residual moisture in freeze dried product was analyzed by a Karl-Fisher type coulometer (Mettler DL37, KF coulometer).
HPLC Analysis
HPLC analysis of samples was done on a Beckman Gold HPLC system.
Vials and Stoppers
Borosilicate 3 ml with 13 mm opening lyo vials and their corresponding butyl rubber stoppers (both from Wheaton) were used for both lyophilization and liquid formulation development. The stoppered vials were capped with Flip-off aluminum caps using a capping device (LW312 Westcapper, The West Company).
There are three main process variables that can be programmed to achieve optimal freeze-drying. Those are shelf temperature, chamber pressure, and lyophilization step duration time. To avoid cake collapse, shelf temperature need to be set at temperatures 2-3° C. below the glass transition or eutectic temperature of the frozen formulation. Both the glass transition and eutectic temperatures of a formulation can be determined by differential scanning calorimetry (DSC) analysis. Chamber pressure is generally set at below the ice vapor pressure of the frozen formulation. The ice vapor pressure is dependent on the shelf temperature and chamber pressure. Too high a chamber pressure will reduce the drying rate by reducing the pressure differential between the ice and the surrounding, while too low a pressure will also slow down drying rate by reducing the heat transfer rate from the shelf to the vials. The development of a lyophilization cycle is closely related with the formulation and the vials chosen for lyophilization. The goal at this stage was to develop a somewhat conservative cycle to be able to successfully freeze dry a number of different formulations. The developed cycles and formulations will be further optimized when viruses are formulated in the formulations. Formulation excipient selection was based on the classical excipients found in most lyophilized pharmaceuticals. The excipients in a lyophilization formulation should provide the functions of bulking, cryoprotection, and lyoprotection. The excipients chosen were mannitol (bulking agent), sucrose (cryo- and lyoprotectant), and human serum albumin (HSA, lyoprotectant). These excipients were formulated in 10 mM Tris+1 mM MgCl2, pH=7.50 at various percentages and filled into the 3 ml vials at a fill volume of 1 ml. To start with, a preliminary cycle was programmed to screen a variety of formulations based on the criteria of residual moisture and physical appearance after drying. The cycle used is plotted in
TABLE 4
Evaluation of Different Formulations Under the Same Cycle
Formulation
M %/S %/HSA %
Appearance
Moisture (% weight)
10/5/0.5
good cake
0.89
5/5/0.5
good cake
1.5
3/5/0.5
loose cake (partial collapse)
3.4
1/5/0.5
no cake (collapse)
6.4
The results suggest that a minimum amount of 3% mannitol is required in the formulation in order to achieve pharmaceutically elegant cake. The percentages of sucrose in the formulation were also examined. No significant effect on freeze-drying was observed at sucrose concentrations of ≦10%. HSA concentration was kept constant to 0.5% during the initial screening stage.
After the evaluation of the formulations, freeze-drying cycle was optimized by changing the shelf temperature, chamber vacuum and the duration of each cycle step. Based on the extensive cycle optimization, the following cycle (cycle #14) was used for further virus lyophilization development.
Effect of Sucrose Concentration in Formulation. Cycle and formulation were further optimized according to virus recovery after lyophilization analyzed by both HPLC and plaque forming unit (PFU) assays. Table 5 shows the virus recoveries immediate after drying in different formulations using the above drying cycle. Variation of the percentage of sucrose in the formulation had significant effect on virus recoveries.
TABLE 5
Recoveries of Virus After Lyophilization
Formulation
M %/S %/HSA %
Appearance
Residual moisture
Recovery (%)
6/0/0.5
good cake
0.44%
0
6/3.5/0.5
good cake
2.2%
56
6/5/0.5
good cake
2.5%
81
6/6/0.5
good cake
2.7%
120
6/7/0.5
good cake
2.8%
120
6/8/0.5
good cake
3.3%
93
6/9/0.5
good cake
3.7%
120
Residual moisture in the freeze-dried product increased as the sucrose percentage increased. A minimum sucrose concentration of 5% is required in the formulation to maintain a good virus recovery after lyophilization. Similar sucrose effects in formulation that had 5% instead of 6% mannitol were observed. However, good virus recovery immediately after drying does not necessary support a good long-term storage stability. As a result, formulations having 4 different sucrose concentrations of 6, 7, 8, and 9%, were incorporated for further evaluation.
Effect of HSA in Formulation. The contribution of HSA concentrations in the formulation on virus recovery after drying was examined using the same freeze drying cycle. Table 6 shows the results.
TABLE 6
Effects of HSA Concentration on Lyophilization
Formulation
M %/S %/HSA %
Appearance
Residual moisture
Recovery (%)
6/7/0
Good cake
0.98
83
6/7/0.5
Good cake
1.24
120
6/7/2
Good cake
1.5
110
6/7/5
Good cake
1.7
102
The results indicate that inclusion of HSA in the formulation had positive effect on virus recovery after drying. Concentrations higher than 0.5% did not further improve the virus recovery post drying. As a result, 0.5% HSA is formulated in all the lyophilization formulations.
Cycle Optimization. As indicated in Table 5, relatively high residual moistures were present in the dried product. Although there has not been a known optimal residual moisture for freeze dried viruses, it could be beneficial for long term storage stability to further reduce the residual moisture in the dried product. After reviewing of the drying cycle, it was decided to increase the secondary drying temperature from 10° C. to 30° C. without increasing the total cycle time. As indicated in Table 7, significant reduction in residual moisture had been achieved in all the formulations without negative effects on virus recoveries. With the improved drying cycle, residual moisture was less than 2% in all the formulations immediately after drying. It is expected that the reduced residual moisture will improve the long-term storage stability of the dried product.
TABLE 7
Effects of Secondary Drying Temperature on Lyophilization
Secondary drying
Secondary drying
at 10° C.
at 30° C.
Formulation
Residual moisture
Recovery
Residual
M %/S %/HSA %
(w %)
(%)
moisture
Recovery
6/6/0.5
2.2
100
0.8
93
6/7/0.5
2.5
86
1.1
100
6/8/0.5
2.7
83
1.3
87
6/9/0.5
3.3
93
1.5
86
5/6/0.5
2.3
110
1.0
94
5/7/0.5
2.7
88
1.2
85
5/8/0.5
3.5
97
1.6
88
5/9/0.5
4
90
1.9
86
N2 Backfilling (Blanketing). Lyophilization was done similarly as above except that dry N2 was used for gas bleeding for pressure control during the drying and backfilling at the end of the cycle. At the end of a drying run, the chamber was filled with dry N2 to about 80% atmospheric pressure. Subsequently, the vials were stoppered. No difference was noticed between the air and N2 blanketing runs immediate after drying. However, if oxygen present in the vial during air backfilling causes damaging effect (oxidation) on the virus or excipients used during long-term storage, backfilling with dry N2 is likely to ameliorate the damaging effects and improve long term storage stability of the virus.
Removal of Glycerol From Formulation. During the preparation of virus containing formulations, stock virus solution was added to the pre-formulated formulations at a dilution factor of 10. Because of the presence of 10% glycerol in the stock virus solution, 1% glycerol was introduced into the formulations. To examine any possible effect of the presence of 1% glycerol on lyophilization, a freeze drying run was conducted using virus diafiltered into the formulation of 5% (M)/7% (S)/0.5% (HSA). Diafiltration was done with 5 vol. of buffer exchange using a constant volume buffer exchange mode to ensure adequate removal of residual glycerol (99% removal). After diafiltration, virus solution was filled into vials and then lyophilized similarly. Table 8 shows the lyophilization results.
TABLE 8
Lyophilization without Glycerol
Formulation
M %/S %/HSA %
Residual moisture
Recovery (%)
5/7/0.5
1.0
80
No significant difference after freeze drying was observed between formulations with and without 1% glycerol. Possible implications of this change on long term storage will be evaluated.
Adp53 virus lyophilized under different formulations and different cycles was placed at −20° C., 4° C., and room temperature (RT) under dark for long term storage stability evaluation. Parameters measured during the stability study were PFU, HPLC viral particles, residual moisture, and vacuum inside vial. The plan is to be able to evaluate virus stability at various conditions for up to one-year storage. Table 6 shows the data after 12-month storage with secondary drying at 10° C. without N2 blanketing. Lyophilized virus is stable at both −20° C. and 4° C. storage for up to 12 months. However, virus was not stable at room temperature storage. More than 50% loss in infectivity was observed at RT after 1-month storage. The reason for the quick loss of infectivity at RT is not clear. However, it is likely that RT is above the glass transition temperature of the dried formulation and resulting in the accelerated virus degradation. A differential scanning caloremitry (DSC) analysis of the formulation could provide very useful information. Pressure change inside the vials during storage was not detected, which indicates that the vials maintained their integrity. The slight increase in residual moisture during storage can be attributed to the release of moisture from the rubber stopper into the dried product.
TABLE 9
Secondary Drying at 10° C.
Formulation Set 10 (6-9)
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Water Content (W %)
Date*
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Apr. 11, 1997
5.5
6.0
5.8
6.5
24.5
24.6
24.9
26.7
2.2
2.5
2.7
3.3
May 15, 1997a
7.6
7.1
7.5
8.1
22.4
25.6
26.8
28.5
2.2
2.5
2.8
3.3
May 15, 1997b
6.6
6.3
6.5
10.0
22.0
23.0
24.0
27.5
2.4
2.6
3.0
3.4
May 15, 1996c
7.1
7.1
6.7
3.3
14.5
16.5
6.2
4.2
2.7
2.9
3.2
3.5
Jul. 18, 1997a
6.8
6.4
6.8
7.2
28.7
28.9
28.6
31.2
2.3
2.5
2.8
3.3
Jul. 18, 1997b
6.0
5.8
7.3
9.0
25.0
26.6
27.6
31.1
2.5
2.8
3.0
3.6
Jul. 18, 1997c
1.2
0.8
4.0
1.4
0.9
1.8
0.7
0.7
2.7
2.9
3.0
3.4
Oct. 22, 1997a
7.9
7.5
7.9
7.8
25.5
25.0
25.4
26.2
2.4
2.6
2.8
3.1
Oct. 22, 1997b
6.8
6.8
5.8
8.0
22.0
23.0
24.7
24.2
2.7
2.9
3.2
3.6
Oct. 22, 1997c
<0.01
<0.01
<0.01
<0.01
N.D.
N.D.
N.D.
N.D.
2.7
2.9
3.1
3.4
Apr. 16, 1998a
6.0
5.8
7.1
7.2
19.3
20.3
23.5
26.1
2.4
2.6
3.0
3.4
Apr. 16, 1998b
5.4
7.2
6.1
6.3
21.7
22.8
22.9
24.6
2.9
3.1
3.3
3.8
Apr. 16, 1998c
0.0003
0.001
0.0007
0.001
N.D.
N.D.
N.D.
N.D.
2.7
2.9
3.1
3.4
*Temp a(−20° C.) b(4° C.) c(r.t.)
Controls
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Date
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Apr. 11, 1997
5.5
7.0
7.0
7.0
35.5
35.8
36.0
36.9
N.D.: not detectable
Formulation set 10: 6%-mannitol, 0.5% HSA, 1% glycerol and different percentages of sucrose in 10 mM-tris buffer pH = 7.5, 1 mM MgCl2
Formulation Set 11 (6-9)
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Water Content (W %)
Date*
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
May 2, 1997
7.0
6.0
6.3
5.8
28.5
28.8
28.4
29.5
2.3
2.7
3.5
4.0
Jun. 20, 1997a
6.2
6.6
6.9
65
26.4
25.0
27.0
27.3
2.2
2.8
34
4.6
Jun. 20, 1997b
6.1
6.0
6.5
6.5
24.1
22.1
25.6
26.6
2.5
2.8
3.5
4.8
Jun. 20, 1997c
3.3
3.0
1.0
<0.1
20.5
17.4
5.2
9.1
2.7
3.1
3.5
4.7
Aug. 18, 1997a
8.0
7.2
7.5
7.6
21.6
21.8
25.3
24.9
2.3
2.8
3.7
4.9
Aug. 18, 1997b
8.0
7.3
8.0
8.0
22.7
22.7
24.9
25.0
2.6
3
3.9
4.2
Aug. 18, 1997c
<0.1
<0.1
<0.1
<0.1
N.D.
N.D.
0.2
13.1
2.7
3.0
3.5
4.4
Oct. 22, 1997a
79
7.5
7.9
6.7
21.0
22.0
25.1
24.0
2.4
3.0
3.9
4.4
Oct. 22, 1997b
6.0
6.9
6.8
7.3
21.4
22.0
23.1
23.1
2.6
3.0
3.3
4.6
Oct. 22, 1997c
<0.01
<0.01
<0.01
<0.015
N.D.
N.D.
N.D.
9.0
2.7
2.9
3.9
5.0
May 8, 1998a
8.3
7.5
8.0
8.7
19.0
18.2
19.9
21.1
2.6
3.1
4.0
4.6
May 8, 1998b
7.0
7.1
7.8
6.5
17.3
17.1
18.2
17.8
2.8
3.2
4.1
5.1
May 8, 1998c
0.00033
0.000065
0.00045
0.000016
N.D.
N.D.
N.D.
N.D.
2.7
2.9
4.0
4.9
*Temp a(−20° C.) b(4° C.) c(R.T.)
Controls
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Date
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
May 2, 1997
6.4
6.8
6.5
6.5
37.7
35.7
37.3
36.0
N.D.: not detectable
Formulation set 11: 5%-mannitol, 0.5% HSA, 1%-glycerol and different percentages of sucrose in 10 mM-tris buffer (pH = 7.5, 1 mM MgCl2)
F11-(6-9)R1-S
TABLE 10
Secondary Drying at 30° C. Without N2 Blanketing
Formulation Set 10 (6-9)
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Water Content (W %)
Date*
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
May 15, 1997
6.5
5.6
6.1
6.0
18.0
18.6
21.9
23.3
0.8
1.1
1.3
1.5
Jun. 20, 1997b
5.4
5.6
5.5
5.5
14.6
14.9
17.2
16.6
0.8
1.2
1.5
1.6
Jun. 20, 1997c
4.5
5.0
5.5
6.0
10.8
11.8
15.0
15.4
1.3
1.4
1.6
1.9
Aug. 18, 1997b
7.0
6.7
6.8
7.0
15.3
17.1
17.9
17.7
1.3
1.5
1.5
1.7
Aug. 18, 1997c
2.4
2.2
4.8
5.8
4.3
7.2
11.7
14.2
1.3
1.6
1.7
2.1
Nov. 20, 1997b
5.5
5.5
5.3
5.7
21.9
21.9
27.2
26.4
1.1
1.4
1.6
1.9
Nov. 20, 1997c
0.5
0.9
2.3
3.1
1.5
6.3
8.8
13.5
1.3
1.7
1.8
2.2
May 14, 1998ab
4.9
4.7
5.4
6.5
9.7
11.9
12.6
14.2
1.2
1.6
2.2
1.4
May 14, 1998c
0.000006
0.00006
0.00004
0.000024
N.D.
N.D.
N.D.
N.D.
1.4
1.6
1.3
2.0
Controls
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Date
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
May 15, 1997
7.0
5.6
7.0
7.0
31.2
30.6
31.6
31.4
Formulation Set 11 (6-9)
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Water Content (W %)
Date*
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
May 22, 1997
7.5
6.3
7.3
6.5
17.4
16.6
20.3
24.7
1.0
1.2
1.6
1.9
Jun. 20, 1997b
5.5
6.3
6.0
7.5
14.8
16.1
17.5
21.1
1.2
1.3
1.7
1.8
Jun. 20, 1997c
5.0
6.0
6.0
7.5
12.6
14.9
17.2
20.3
1.4
1.6
1.9
2.0
Aug. 18, 1997b
6.3
6.7
68
7.5
15.7
17.2
18.5
22.6
1.2
1.5
1.8
1.9
Aug. 18, 1997c
3.3
4.5
5.5
7.0
7.4
10.5
15.8
21.2
1.6
1.7
1.9
2.2
Nov. 20, 1997b
5.3
5.6
5.3
6.6
22.6
26.4
30.0
35.0
1.2
1.4
1.9
1.9
Nov. 20, 1997c
0.8
1.9
3.0
0.1
3.2
9.6
18.3
1.3
1.6
1.7
2.0
2.1
May 14, 1998b
6.7
7.2
6.9
7.6
12.4
13.9
15.5
18.5
1.3
1.6
2.0
2.2
May 14, 1998c
0.0013
0.00005
0.00031
0.00045
N.D.
N.D.
N.D.
N.D.
1.6
1.8
1.6
2.0
Controls
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Date
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
May 22, 1997
8.0
7.4
8.3
7.6
26.7
27.6
27.5
32.4
*Temp
ab(4° C.)
a(−20° C.)
b(4° C.)
c(R.T.)
Formulation set 10: 6%-mannitol, 0.5% HSA, 1%-glycerol and different percentages of sucrose in 10 mM-tris buffer (pH = 7.5, 1 mM MgCl2)
F10(6-9)R2-S
Formulation set 11: 5%-mannitol, 0.5% HSA, 1%-glycerol and different percentages of sucrose in 10 mM-tris buffer (pH = 7.5, 1 mM MgCl2)
F11-(6-9)R2-S
TABLE 11
Secondary Drying at 30° C. With N2 Blanketing
Formulation Set 10 (6-9) + Adp53
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Water Content (W %)
Date*
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Jun. 13, 1997
3.4
4.3
4.1
4.2
16.0
16.5
16.1
18.1
0.8
1.1
1.3
1.4
Jul. 18, 1997b
6.3
6.3
6.0
6.0
17.9
19.5
19.9
20.6
0.9
1.2
1.4
1.6
Jul. 18, 1997c
4.1
5.5
5.0
5.5
11.4
15.5
18.2
20.6
1.2
1.4
1.7
1.8
Sep. 16, 1997b
4.2
5.5
4.5
5.1
15.3
16.1
16.4
17.8
1.0
1.3
1.5
1.7
Sep. 16, 1997c
0.7
1.2
5.0
4.0
2.9
5.0
9.5
13.0
1.3
1.5
1.8
2.0
Dec. 4, 1997b
5.5
5.3
5.4
5.9
16.1
16.2
18.1
18.5
1.1
1.4
1.6
1.7
Dec. 4, 1997c
0.3
0.5
2.5
3.4
N.D.
1.7
4.7
8.8
1.4
1.6
1.8
2.0
Jun. 29, 1998ab
3.8
5.1
5.3
5.4
10.6
10.8
12.0
12.9
1.3
1.5
1.8
1.9
Jun. 29, 1998c
0.00003
0.00006
0.0001
0.0001
N.D.
N.D.
N.D.
N.D.
1.4
1.6
1.7
1.8
Controls
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Date
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Set 10-6
Set 10-7
Set 10-8
Set 10-9
Jun. 13, 1997
4.7
3.8
5.5
6.2
26.0
26.2
27.4
27.5
Formulation set 11 (6-9) + Adp53
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Water Content (W %)
Date*
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Jun. 13, 1997
3.4
4.2
3.6
4.4
16.1
16.3
18.4
19.3
0.9
1.3
1.8
1.9
Jul. 18, 1997b
5.5
6.2
6.5
6.2
18.0
19.5
23.0
23.9
1.0
1.4
1.8
2.1
Jul. 18, 1997c
3.7
6.0
6.7
7.3
13.7
18.7
21.8
22.8
1.3
1.7
2.0
2.2
Sep. 16, 1997b
3.9
4
4.6
6
15.6
17.3
19.5
20.6
1.3
1.5
1.9
2.1
Sep. 16, 1997c
0.78
2.2
4.0
5.3
3.6
6.8
13.8
14.6
1.5
1.9
2.3
2.4
Dec. 4, 1997b
4.6
5.3
8.0
6.1
15.7
18.2
21.4
21.6
1.2
1.6
2.1
2.2
Dec. 4, 1997c
0.4
0.6
0.3
0.01
N.D.
N.D.
1.7
N.D.
1.6
1.8
2.1
2.1
Jun. 29, 1998ab
4.9
5.0
5.4
6.4
11.4
14.2
13.7
16.0
1.5
1.7
2.1
2.6
Jun. 29, 1998c
0.0001
0.00015
0.00085
0.0012
N.D.
ND.
N.D.
N.D.
1.6
1.7
2.2
2.3
Controls
PFU × 109/ml
HPLC Viral Particle (×1010/ml)
Date
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Set 11-6
Set 11-7
Set 11-8
Set 11-9
Jun. 13, 1997
4.5
5.0
4.0
5.0
26.5
26.9
26.6
27.1
*Temp.
ab(4° C.)
c(R.T.)
Formulation set 10: 6%-mannitol, 0.5% HSA, 1%-glycerol and different percentages of sucrose in 10 mM-tris buffer (pH: 7.5, 1 mM MgCl2)
Formulation set 11: 6%-mannitol, 0.5% HSA, 1%-glycerol and different percentages of sucrose in 10 mM-tris buffer (pH = 7.5, 1 mM MgCl2)
F11-(6-9)R3-S
TABLE 12
Aqueous Formulation Set #1
Date
(Storage Conds.)
10%-G
5%-S + 5%-HSA
5%-S + 1%-PEG
5%-T + 1%-PEG
PFU × 109/ml
Aug. 1, 1997
5.8
4.7
4.3
4.4
Aug. 28, 1997 (4° C., N2)
5.8
5.8
6.4
6.3
Aug. 28, 1997 (4° C.,. Air)
5.0
5.9
6.0
5.9
Aug. 28, 1997 (R.T., N2)
4.4
4.8
5.0
6.0
Aug. 28, 1997 (R.T., Air)
4.3
5.0
5.0
5.6
Oct. 30, 1997 (4° C., N2)
3.8
4.0
4.7
3.8
Oct. 30, 1997 (4° C. Air)
3.0
4.1
3.7
4.7
Oct. 30, 1997 (R.T., N2)
1.5
3.4
3.5
3.6
Oct. 30, 1997 (R.T., Air)
1.5
3.6
2.2
3.1
Jan. 12, 1998 (4° C., N2)
3.2
4.1
3.3
3.4
Jan. 12, 1998 (4° C., Air)
1.5
3.8
3.9
3.4
Jan. 12, 1998 (R.T., N2)
0.1
1.4
0.7
0.7
Jan. 12, 1998 (R.T., Air)
0.4
1.6
1.0
0.4
Apr. 30, 1998 (4° C., N2)
0.08
4.3
4.0
5.3
Apr. 30, 1998 (4° C., Air)
1.5
3.6
4.4
4.5
Apr. 30, 1998 (R.T., N2)
0.0025
0.23
0.11
0.17
Apr. 30, 1998 (R.T., Air)
0.0015
0.21
0.063
0.007
Feb. 5, 1999 (4° C., N2)
0.0005
5.8
4.1
3.9
Feb. 5, 1999 (4° C., Air)
0.02
4.7
4.3
4.5
Feb. 5, 1999 (R.T., N2)
<102
0.0007
<104
0.0002
Feb. 5, 1999 (R.T., Air)
2 × 102
0.0002
0.0003
2 × 103
HPLC Viral Particle (×1010/ml)
Aug. 1, 1997
16.9
14.5
16.1
16.7
Aug. 28, 1997 (4° C., N2)
13.3
14.9
13.8
13.4
Aug. 28, 1997 (4° C., Air)
12.9
14.2
12.9
12.9
Aug. 28, 1997 (R.T., N2)
12.6
14.5
13.5
12.9
Aug. 28, 1997 (R.T., Air)
12.3
13.7
13.0
13.0
Oct. 30, 1997 (4° C., N2)
14.0
15.5
14.7
14.8
Oct. 30, 1997 (4° C., Air)
12.6
14.9
14.3
14.4
Oct. 30, 1997 (R.T., N2)
13.8
15.1
14.6
14.4
Oct. 30, 1997 (R.T., Air)
12.7
14.7
14.8
14.4
Jan. 12, 1998 (4° C., N2)
7.3
11.1
9.5
9.5
Jan. 12, 1998 (4° C., Air)
7.7
10.8
10.2
10.0
Jan. 12, 1998 (R.T., N2)
10.0
10.8
11.1
10.4
Jan. 12, 1998 (R.T., Air)
9.9
11.0
10.0
10.4
Apr. 30, 1998 (4° C., N2)
5.1
12.3
12.3
12.1
Apr. 30, 1998 (4° C., Air)
5.0
11.6
11.8
11.9
Apr. 30, 1998 (R.T., N2)
11.1
12.3
12.6
12.5
Apr. 30, 1998 (R.T., Air)
11.0
12.4
12.3
11.0
Feb. 5, 1999 (4° C., N2)
3.4
5.8
11.4
11.0
Feb. 5, 1999 (4° C., Air)
3.9
7.1
11.0
11.2
Feb. 5, 1999 (R.T., N2)
10.1
7.9
8.5
10.9
Feb. 5, 1999 (R.T., Air)
9.7
7.1
10.3
9.3
G: glycerol
S: sucrose
PEG: PEG-3500
T: trehalose
Glycerol: 10% glycerol in DPBS buffer
Other formulations are in 10 mM-tris buffer with 0.15 M-NaCl and 1 mM-MgCl2 (pH = 8.2).
TABLE 13
Aqueous Formulation Set #2
PFU × 109/ml
Date (Temp.)
AQF2-1
AQF2-2
AQF2-3
AQF2-4
AQF2-5
AQF2-6
AQF2-7*
Sep. 25, 1997
2.8
2.8
2.8
3.0
2.8
2.8
2.7
Nov. 05, 1997 (4° C.)
2.3
3.2
2.4
3.6
2.7
2.0
3.6
Nov. 05, 1997 (R.T.)
1.4
1.9
1.3
1.5
2.4
2.5
3.1
Dec. 12, 1997 (4° C.)
2.2
0.1
2.4
2.7
2.1
2.1
3.2
Jan. 09, 1998 (R.T.)
1.2
0.1
0.2
1.2
0.2
0.1
1.3
PFU × 109/ml
Date (Temp.)
AQF2-8*
AQF2-9*
AQF2-10*
AQF2-11*
AQF2-12
Sep. 25, 1997
2.8
2.7
3.3
3.1
2.7
Nov. 05, 1997 (4° C.)
3.8
2.7
3.0
3.5
2.5
Nov. 05, 1997 (R.T.)
3.3
3.1
4.1
2.8
1.1
Dec. 12, 1997 (4° C.)
2.1
3.0
3.0
3.4
2.9
Jan. 09, 1998 (R.T.)
1.1
0.2
0.1
20
1.1
HPLC viral particle (×1010/ml)
Date (Temp.)
AQF2-1
AQF2-2
AQF2-3
AQF2-4
AQF2-5
AQF2-6
AQF2-7
Sep. 25, 1997
10.9
9.6
9.7
11.3
10.7
10.6
10.9
Nov. 05, 1997 (4° C.)
7.9
7.6
8.7
8.8
8.9
7.5
8.6
Nov. 05, 1997 (R.T.)
8.2
6.6
7.6
8.6
7.7
9.3
9.0
Dec. 12, 1997 (4° C.)
6.7
1.5
8.0
6.9
5.2
7.5
7.5
Dec. 17, 1997 (R.T.)
7.0
1.2
7.0
7.5
4.1
7.1
7.0
HPLC viral particle ×1010/ml)
Date (Temp.)
AQF2-8
AQF2-9
AQF2-10
AQF2-11
AQF2-12
Sep. 25, 1997
10.8
10.7
11.4
11.8
10.7
Nov. 05, 1997 (4° C.)
9.1
9.2
10.3
11.2
9.6
Nov. 05, 1997 (R.T.)
8.0
9.3
10.3
11.1
9.6
Dec. 12, 1997 (4° C.)
6.1
7.6
8.8
7.3
7.7
Dec. 17, 1997 (R.T.)
3.0
8.2
7.6
8.4
7.5
Aqueous Formulation Set 2
Excipients
AQF2-1
AQF2-2
AQF2-3
AQF2-4
AQF2-5
AQF2-6
AQF2-7
mannitol (W %)
5
5
5
5
sucrose (W %)
5
5
5
5
glycine (M)
0.25
0.25
0.25
arginine (M)
0.25
0.25
urea (W %)
1
1
peg (w %)
Excipients
AQF2-8
AQF2-9
AQF2-10
AQF2-11
AQF2-12
mannitol (W %)
5
5
5
5
sucrose (W %)
5
5
5
5
10
glycine (M)
0.25
0.25
arginine (M)
0.25
0.25
urea (W %)
1
1
peg (w %)
1
1
*Gave better recovery.
Formulations are in 10 mM-tris buffer (pH = 7.5) which consists of 1% glycerol and 1 mM MgCl2.
The formulations are stored at 4° C. and room temperature under nitrogen.
TABLE 14
Aqueous Formulation Set #3
HPLC Viral Particle
PFU × 109
(×109/ml)
Date (temp.)
F10-7
F10-8
F11-7
F11-8
F10-7
F10-8
F11-7
F11-8
Oct. 3, 1997
2.2
3.3
2.1
2.8
12.1
12.0
11.8
12.0
Nov. 6, 1997
3.4
4.0
2.8
3.4
10.6
10.5
10.1
10.3
(−20° C.)
Nov. 6, 1997
3.5
3.6
4.3
2.8
10.0
9.7
9.9
10.3
(4° C.)
Jan. 15, 1998
3.8
4.8
3.2
3.7
7.3
7.4
7.7
8.0
(−20° C.)
Jan. 15, 1998
3.5
3.1
2.9
3.1
7.5
7.4
7.6
7.5
(4° C.)
Excipients
F10-7
F10-8
F11-7
F11-8
mannitol (W %)
6
6
5
5
sucrose (VV %)
7
8
7
8
HSA (W %)
0.5
0.5
0.5
0.5
glycerol (W %)
1
1
1
1
MgCl2 (mM)
1
1
1
1
TABLE 15
Liquid formulation set #4
PFU (×109/ml)
Date (Temp.)
AQF4-1
AQF4-2
AQF4-3
AQF4-4
AQF4-5
AQF4-6
AQF4-7
Jan. 13, 1998
3.0
2.5
3.6
3.4
2.7
3.1
3.4
Feb. 16, 1998 (4° C.)
2.5
3.2
3.3
2.9
2.6
2.9
2.6
Feb. 16, 1998 (R.T.)
1.8
2.7
1.6
3.6
2.6
1.6
1.7
Apr. 10, 1998 (4° C.)
2.2
2.0
2.6
3.0
2.4
1.9
2.2
Apr. 10, 1998 (R.T.)
0.4
0.4
0.3
0.5
0.4
<0.1
1.1
Jul. 24, 1998 (4° C.)
2.4
2.8
2.6
3.5
1.9
2.2
2.6
Jul. 24, 1998 (R.T.)
0.002
0.005
0.006
0.005
0.005
0.005
0.001
Jan. 8, 1999 (4° C.)
2.9
2.4
2.1
2.6
2.0
2.2
2.1
Jan. 8, 1999 (R.T.)
0.0002
0.0004
0.0004
0.0002
0.0004
0.0004
0.00006
HPLC Viral Particles (×1010/ml)
Date (Temp.)
AQF4-1
AQF4-2
AQF4-3
AQF4-4
AQF4-5
AQF4-6
AQF4-7
Jan. 13, 1998
7.2
8.8
9.2
9.0
7.8
7.9
9.1
Feb. 16, 1998 (4° C.)
7.5
9.3
9.2
9.5
8.2
8.4
9.6
Feb. 16, 1998 (R.T.)
6.8
9.0
9.5
9.0
8.7
8.4
9.3
Apr. 10, 1998 (4° C.)
7.1
9.2
9.6
9.6
8.9
9.1
9.9
Apr. 10, 1998 (R.T.)
7.5
9.5
10.1
9.7
8.9
8.9
9.5
Jul. 24, 1998 (4° C.)
8.1
9.9
11.1
10.3
9.2
7.4
9.3
Jul. 24, 1998 (R.T.)
7.3
3.0
10.7
8.9
10.4
10.45
3.5
Jan. 8, 1999 (4° C.)
7.8
10.3
10.3
10.1
8.7
1.7
9.5
Jan. 8, 1999 (R.T.)
8.4
11.0
11.3
11.0
9.7
10.4
9.4
Excipients
AQF4-1
AQF4-2
AQF4-3
AQF4-4
AQF4-5
AQF4-6
AQF4-7
Mannitol (w %)
5
5
5
5
5
5
5
Sucrose (w %)
5
5
5
5
5
5
5
Tween-80 (w %)
0.02
0.1
0.5
Chap (w %)
0.02
0.1
0.5
Buffer: 10 mM Tris + H0.15 M NaCl + 1 mM MgCl2, pH = 8.2
Formulations were blanketed with N2.
Table 10 and Table 11 show the storage stability data with secondary drying at 30° C. without and with N2 backfilling, respectively. Because of the nearly identical stability observed at −20° C. and 4° C. storage conditions, and to reduce the consumption of virus, −20° C. was not included in the long-term storage stability study. Similar to the samples dried with secondary drying at 10° C., virus is stable at 4° C. but not stable at RT. However, relative better stability was observed at RT storage than those dried at 10° C. secondary drying. This is likely to be the result of the lower residual moisture attained at 30° C. secondary drying. This result suggests that residual moisture is an important parameter that affects storage stability during long term storage.
HPLC viral particle recoveries are consistently lower than virus recoveries calculated from PFU assay immediate after drying. The reason for the discrepancy is not clear. However, it is likely to be related to possible virus aggregation during freeze-drying. Electron microscopy evaluation is being carried out to examine possible virus aggregation after lyophilization. During storage, HPLC analysis indicates that virus is stable at both −20° C. and 4° C. storage and not stable at RT, which is consistent with the results from PFU assay.
The presence of HSA in the formulations could be a potential regulatory concern. As a result, a variety of excipients have been evaluated to substitute HSA in the formulation. The substitutes examined included PEG, amino acids (glycine, arginine), polymers (polyvinylpyrrolidone), and surfactants (Tween-20 and Tween-80). These HSA substitutes are, however, suboptimal relative to HSA. Effort on further development was minimal.
Concurrent with the development of lyophilization of Adp53 product, experimentation was carried out to examine the possibility of developing a liquid formulation for Adp53 product. The goal was to develop a formulation that can provide enough stability to the virus when stored at above freezing temperatures. Four sets of liquid formulations have been evaluated. In the first set of formulation, the current 10% glycerol formulation was compared to HSA and PEG containing formulations. In the second set of formulation, various amino acids were examined for formulating Adp53. In the third set of formulation, the optimal formulation developed for lyophilization was used to formulate Adp53 in a liquid form. In the fourth set of formulation, detergents were evaluated for formulating Adp53. Viruses formulated with all those different formulations are being tested for long term storage stability at −20° C., 4° C., and RT.
Liquid Formulation Set #1
HSA containing formulation (5% sucrose+5% HSA in 10 mM Tris buffer, 150 mM NaCl, and 1 mM MgCl2, pH=8.20 buffer) was compared with 10% glycerol in DPBS buffer and sucrose/PEG and Trehalose/PEG formulations. PEG has been recommended as a good preferential exclusion agent in formulations (Wong and Parasrampurita, 1997). It is included in this set of formulation to examine whether it can provide stabilization effect on Adp53. Formulations were filled into the 3 ml lyo vials at a fill volume of 0.5 ml. Vials were capped under either atmospheric or N2 blanketing conditions to examine any positive effects N2 blanketing may have on long term storage stability of Adp53. To ensure adequate degassing from the formulation and subsequent N2 blanketing, the filled vials was partially stoppered with lyo stoppers and loaded onto the shelf of the lyophilizer under RT. The lyophilizer chamber was closed and vacuum was established by turning on the vacuum pump. The chamber was evacuated to 25 in Hg. Then the chamber was purged completely with dry N2. The evacuation and gassing were repeated twice to ensure complete N2 blanketing. N2 blanketed vials were placed with the non-N2 blanketed vials at various storage conditions for storage stability evaluation. Table 12 shows the analysis data for up to 18 months storage at 4° C. and RT.
Statistically significant drops in virus PFU and HPLC viral particles were observed for 10% glycerol formulation after 3 months storage at both 4° C. and RT. No statistically significant virus degradation was observed for all other formulations at 4° C. storage. However, decrease in virus infectivity was observed when stored at RT.
Liquid Formulation Set #2
Various combinations of amino acids, sugars, PEG and urea were evaluated for Adp53 stabilization during long storage. Table 13 shows the 12-month stability data. The results indicate that combination of 5% mannitol and 5% sucrose with other excipients gave better storage stability at RT for one month. Adp53 is most stable in formulation has all the excipients. In this set of formulation, no human or animal derived excipients were included. It is our expectation to develop a liquid formulation without including any proteins derived from either human or animal origins.
Liquid Formulation Set #3
The optimal formulations developed for lyophilization was evaluated for formulating Adp53 in a liquid form. This approach would be a good bridging between liquid formulation and lyophilization if satisfactory Adp53 stability can be achieved using lyophilization formulation for liquid fill. Filled samples were stored at −20° C. and 4° C. for stability study. Table 14 shows the 3-month stability data. Virus is stable at both −20° C. and 4° C. for the four different formulations. This is in agreement with the results from formulation set #2, which suggests that better virus stability is expected with the presence of both mannitol and sucrose in the formulation. Longer time storage stability data is being accrued.
Liquid Formulation Set #4
Detergents have been used in the formulations for a variety of recombinant proteins. In this set of formulation, various concentrations of detergents were examined for formulating Adp53. The detergents used were non-ionic (Tween-80) and zwitterionic (Chap). Table 15 shows the 12-month stability data. Virus is stable at 4° C. storage. No significant difference in virus stability at 4° C. was observed among the formulations tested. Similar to formulation set #2, no exogenous protein is included in this set of formulation.
All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
| Patent | Priority | Assignee | Title |
| 10752876, | Sep 02 2015 | McMaster University | Enhanced thermal stability for adenoviral vectors through spray drying |
| 9254332, | Mar 15 2013 | ARECOR LIMITED | Stable aqueous formulations of adenovirus vectors |
| 9744242, | Mar 15 2013 | ARECOR LIMITED | Stable aqueous formulations of adenovirus vectors |
| Patent | Priority | Assignee | Title |
| 4352883, | Oct 23 1978 | REPLIGEN CORPORATION A CORP OF DELAWARE | Encapsulation of biological material |
| 4725547, | Aug 10 1984 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for purfication of rabic virus |
| 4797368, | Mar 15 1985 | The United States of America as represented by the Department of Health; HEALTH AND HUMAN SERVICES, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF | Adeno-associated virus as eukaryotic expression vector |
| 5139941, | Oct 31 1985 | University of Florida Research Foundation, Incorporated | AAV transduction vectors |
| 5219752, | May 25 1988 | Teijin, Limited | Process for continuously culturing adherent animal cells |
| 5552309, | Sep 30 1994 | Advanced Research & Technology Institute | Use of polyols for improving the introduction of genetic material into cells |
| 5607851, | Jun 18 1991 | CHIRON S R L | Process for purifying hepatitis a virus (HAV), and vaccine compositions containing hepatitis a virus |
| 5744304, | May 30 1995 | Board of Regents, The University of Texas System | Inflammation-induced expression of a recombinant gene |
| 5789244, | Jan 08 1996 | CANJI INC | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
| 5837520, | Mar 07 1995 | Canji, Inc. | Method of purification of viral vectors |
| 6143290, | Oct 29 1993 | The Board of Regents, University of Texas System | Tumor regression by adenovirus expression of wild-type p53 |
| 6168944, | Jan 31 1997 | Merck Sharp & Dohme Corp | Methods for cultivating cells and propagating viruses |
| 6194191, | Nov 20 1996 | CRUCELL HOLLAND B V | Method for the production and purification of adenoviral vectors |
| 6194210, | Mar 08 1994 | Merck & Co., Inc. | Hepatitis A virus culture process |
| 6383795, | Apr 22 1998 | GENVEC, INC | Efficient purification of adenovirus |
| 6485958, | Jul 01 1996 | Centelion | Method for producing recombinant adenovirus |
| 6521225, | Sep 06 1996 | Chiron Corporation | AAV vectors |
| 6537793, | Dec 31 1998 | Centelion | Method of separating viral particles |
| 6586226, | Apr 22 1998 | GenVec, Inc. | Efficient purification of adenovirus |
| 6689600, | Nov 16 1998 | CRUCELL HOLLAND B V | Formulation of adenovirus for gene therapy |
| 6726907, | Nov 20 1996 | CRUCELL HOLLAND B V | Purified adenoviral compositions |
| 7125706, | Nov 20 1996 | CRUCELL HOLLAND B V | Method for the production and purification of adenoviral vectors |
| 20020018723, | |||
| 20020094577, | |||
| 20020177215, | |||
| 20030008375, | |||
| 20030166603, | |||
| 20050089999, | |||
| 20060035857, | |||
| 20070155008, | |||
| EP273085, | |||
| EP475623, | |||
| JP1279843, | |||
| JP49338, | |||
| WO32754, | |||
| WO34444, | |||
| WO9318790, | |||
| WO9325224, | |||
| WO9406910, | |||
| WO9417178, | |||
| WO9506743, | |||
| WO9510601, | |||
| WO9519427, | |||
| WO9525789, | |||
| WO9609399, | |||
| WO9627677, | |||
| WO9632116, | |||
| WO9704803, | |||
| WO9708298, | |||
| WO9800524, | |||
| WO9822588, | |||
| WO9826048, | |||
| WO9835554, | |||
| WO9912568, | |||
| WO9941416, | |||
| WO9954441, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Oct 29 2007 | Crucell Holland B.V. | (assignment on the face of the patent) | / | |||
| May 15 2009 | INTROGEN THERAPEUTICS, INC | CRUCELL HOLLAND B V | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023279 | /0858 |
| Date | Maintenance Fee Events |
| Aug 13 2014 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Aug 02 2018 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Oct 03 2022 | REM: Maintenance Fee Reminder Mailed. |
| Mar 20 2023 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Feb 15 2014 | 4 years fee payment window open |
| Aug 15 2014 | 6 months grace period start (w surcharge) |
| Feb 15 2015 | patent expiry (for year 4) |
| Feb 15 2017 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Feb 15 2018 | 8 years fee payment window open |
| Aug 15 2018 | 6 months grace period start (w surcharge) |
| Feb 15 2019 | patent expiry (for year 8) |
| Feb 15 2021 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Feb 15 2022 | 12 years fee payment window open |
| Aug 15 2022 | 6 months grace period start (w surcharge) |
| Feb 15 2023 | patent expiry (for year 12) |
| Feb 15 2025 | 2 years to revive unintentionally abandoned end. (for year 12) |